

ARTICLE

Received 12 Mar 2015 | Accepted 27 Oct 2015 | Published 21 Jan 2016

DOI: 10.1038/ncomms10023

OPEN

Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function

Cristian Pattaro *et al.*[#]

Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways.

Correspondence and requests for materials should be addressed to C.P. (email: cristian.pattaro@eurac.edu) or to A.K. (email: anna.koettgen@uniklinik-freiburg.de) or to C.S.F. (email: foxca@nhlbi.nih.gov).

[#]A full list of authors and their affiliations appears at the end of the paper.

Chronic kidney disease (CKD) is a global public health problem^{1–3}, and is associated with an increased risk for cardiovascular disease, all-cause mortality and end-stage renal disease^{4,5}. Few new therapies have been developed to prevent or treat CKD over the past two decades^{1,6}, underscoring the need to identify and understand the underlying mechanisms of CKD.

Prior genome-wide association studies (GWAS) have identified multiple genetic loci associated with CKD and estimated glomerular filtration rate (eGFR), a measure of the kidney's filtration ability that is used to diagnose and stage CKD^{7–15}. Subsequent functional investigations point towards clinically relevant novel mechanisms in CKD that were derived from initial GWAS findings¹⁶, providing proof of principle that locus discovery through large-scale GWAS efforts can translate to new insights into CKD pathogenesis.

To identify additional genetic variants associated with eGFR and guide future experimental studies of CKD-related mechanisms, we have now performed GWAS meta-analyses in up to 133,413 individuals, more than double the sample size of previous studies. Here we describe multiple novel genomic loci associated with kidney function traits and provide extensive locus characterization and bioinformatics analyses, further delineating the physiologic basis of kidney function.

Results

Stage 1 discovery analysis. We analysed associations of eGFR based on serum creatinine (eGFR_{crea}), cystatin C (eGFR_{cys}, an additional, complementary biomarker of renal function) and CKD (defined as eGFR_{crea} <60 ml min⁻¹ per 1.73 m²) with ~2.5 million autosomal single-nucleotide polymorphisms (SNPs) in up to 133,413 individuals of European ancestry from 49 predominantly population-based studies (Supplementary Table 1). Results from discovery GWAS meta-analysis are publicly available at <http://fox.nhlbi.nih.gov/CKDGen/>. We performed analyses in each study sample in the overall population and stratified by diabetes status, since genetic susceptibility to CKD may differ in the presence of this strong clinical CKD risk factor. Population stratification did not impact our results as evidenced by low genomic inflation factors in our meta-analyses, which ranged from 1.00 to 1.04 across all our analyses (Supplementary Fig. 1).

In addition to confirming 29 previously identified loci^{7–9} (Fig. 1a; Supplementary Table 2), we identified 48 independent novel loci (Supplementary Table 3) where the index SNP, defined as the variant with the lowest *P* value in the region, had an association *P* value <1.0 × 10⁻⁶. Of these 48 novel SNPs, 21 were genome-wide significant with *P* values <5.0 × 10⁻⁸. Overall, 43 SNPs were identified in association with eGFR_{crea} (nine in the non-diabetes sample), one with eGFR_{cys} and four with CKD, as reported in Supplementary Table 3. Manhattan plots for CKD, eGFR_{cys} and eGFR_{crea} in diabetes are shown in Fig. 1b,c and Supplementary Fig. 2, respectively.

Stage-2 replication. Novel loci were tested for replication in up to 42,166 additional European ancestry individuals from 15 studies (Supplementary Table 1). Of the 48 novel candidate SNPs submitted to replication, 24 SNPs demonstrated a genome-wide significant combined stage 1 and 2 *P* value <5.0 × 10⁻⁸ (Table 1). Of these, 23 fulfilled additional replication criteria (*q*-value <0.05 in stage 2). Only rs6795744 at the *WNT7A* locus demonstrated suggestive replication (*P* value <5.0 × 10⁻⁸, *q*-value >0.05). Because serum creatinine is used to estimate eGFR_{crea}, associated genetic loci may be relevant to creatinine production or metabolism rather than kidney function *per se*. For this reason, we contrasted associations of eGFR_{crea} versus eGFR_{cys}, the latter estimated from an alternative and

creatinine-independent biomarker of GFR (Supplementary Fig. 3; Supplementary Table 4). The majority of loci (22/24) demonstrated consistent effect directions of their association with both eGFR_{crea} and eGFR_{cys}.

Association plots of the 24 newly identified genomic regions that contain a replicated or suggestive index SNP appear in Supplementary Fig. 4. The odds ratio for CKD for each of the novel loci ranged from 0.93 to 1.06 (Supplementary Table 4). As evidenced by the relatively small effect sizes, the proportion of phenotypic variance of eGFR_{crea} explained by all new and known loci was 3.22%: 0.81% for the newly uncovered loci and 2.41% for the already known loci.

Associations stratified by diabetes and hypertension status. The effects of the 53 known and novel loci in individuals with (stage 1 + stage 2 *n* = 16,477) and without (stage 1 + stage 2 *n* = 154,881) diabetes were highly correlated (correlation coefficient: 0.80; 95% confidence interval: 0.67, 0.88; Supplementary Fig. 5) and of similar magnitude (Fig. 2; Supplementary Table 5), suggesting that identification of genetic loci in the overall population may also provide insights into loci with potential importance among individuals with diabetes. The previously identified *UMOD* locus showed genome-wide significant association with eGFR_{crea} among those with diabetes (Supplementary Fig. 2; rs12917707, *P* value = 2.5 × 10⁻⁸), and six loci (*NFKB1*, *UNCX*, *TSPAN9*, *AP5B1*, *SIPA1L3* and *PTPRO*) had nominally significant associations with eGFR_{crea} among those with diabetes. Of the previously identified loci, 13 demonstrated nominal associations among those with diabetes, for a total of 19 loci associated with eGFR_{crea} in diabetes.

Exploratory comparison of the association effect sizes in subjects with and without hypertension based on our previous work⁷ showed that novel and known loci are also similarly associated with eGFR_{crea} among individuals with and without hypertension (Supplementary Fig. 6).

Tests for SNP associations with related phenotypes. We tested for overlap with traits that are known to be associated with kidney function in the epidemiologic literature by investigating SNP associations with systolic and diastolic blood pressure¹⁷, myocardial infarction¹⁸, left ventricular mass¹⁹, heart failure²⁰, fasting glucose²¹ and urinary albumin excretion (CKDGen Consortium, personal communication). We observed little association of the 24 novel SNPs with other kidney function-related traits, with only 2 out of 165 tests reaching the Bonferroni significance level of 0.0003 (see Methods and Supplementary Table 6).

To investigate whether additional traits are associated with the 24 new eGFR loci, we queried the NHGRI GWAS catalog (www.genome.gov). Overall, nine loci were previously identified in association with other traits at a *P* value of 5.0 × 10⁻⁸ or lower (Supplementary Table 7), including body mass index (*ETV5*) and serum urate (*INHBC*, *AICF* and *AP5B1*).

Trans-ethnic analyses. To assess the generalizability of our findings across ethnicities, we evaluated the association of the 24 newly identified loci with eGFR_{crea} in 16,840 participants of 12 African ancestry population studies (Supplementary Table 8) and in up to 42,296 Asians from the AGEN consortium¹¹ (Supplementary Table 9). Seven SNPs achieved nominal direction-consistent significance (*P* <0.05) in AGEN, and one SNP was significant in the African ancestry meta-analysis (Supplementary Table 9). Random-effect meta-analysis showed that 12 loci (*SDCCAG8*, *LRP2*, *IGFBP5*, *SKIL*, *UNCX*, *KBTBD2*, *AICF*, *KCNQ1*, *AP5B1*, *PTPRO*, *TP53INP2* and *BCAS1*) had fully consistent effect direction across the three ethnic groups




Figure 1 | Discovery stage genome-wide association analysis. Manhattan plots for eGFRcrea, CKD and eGFRcys. Previously reported loci are highlighted in light blue (grey labels). **(a)** Novel loci uncovered for eGFRcrea in the overall and in the non-diabetes groups are highlighted in blue and green, respectively. **(b)** Results from CKD analysis with highlighted known and novel loci for eGFRcrea. **(c)** Results from eGFRcys with highlighted known and novel loci for eGFRcrea and known eGFRcys loci.

Table 1 | The 24 novel SNPs associated with eGFRcrea in European ancestry individuals.

SNP ID*	Chr.	Position (bp) [†]	Locus name [‡]	Effect/Non effect allele (EAF)	SNP function [§]	Stage 1 (discovery)		Stage 2 (replication)		Combined analysis [#]		
						Beta	P value	Beta	q-value	Beta	P value [#]	I ² % ^{**}
The eight loci whose smallest P value was observed in the 'no diabetes' group												
rs3850625	1	201,016,296	CACNA1S	A/G (0.12)	Exonic, nonsyn. SNV	0.0080	2.55E-09	0.0071	5.46E-03	0.0083	6.82E-11	0
rs2712184	2	217,682,779	IGFBP5	A/C (0.58)	Intergenic	-0.0049	1.65E-08	-0.0055	2.06E-03	-0.0053	1.33E-10	0
rs9682041	3	170,091,902	SKIL	T/C (0.87)	Intronic	-0.0067	1.36E-07	-0.0046	2.33E-02	-0.0068	2.58E-08	2
rs10513801	3	185,822,353	ETV5	T/G (0.87)	Intronic	0.0070	3.80E-09	0.0046	1.79E-02	0.0072	1.03E-09	0
rs10994860	10	52,645,424	AICF	T/C (0.19)	UTRS	0.0075	1.00E-11	0.0061	5.46E-03	0.0077	1.07E-12	2
rs163160	11	2,789,955	KCNQ1	A/G (0.82)	Intronic	0.0067	9.02E-09	0.0050	9.89E-03	0.0065	2.26E-09	14
rs164748	16	89,708,292	DPEP1	C/G (0.53)	Intergenic	0.0047	9.92E-09	0.0019	4.19E-02	0.0046	1.95E-08	17
rs8091180	18	77,164,243	NFATC1	A/G (0.56)	Intronic	-0.0054	1.43E-08	-0.0052	5.46E-03	-0.0060	1.28E-09	0
The 16 loci whose smallest P value was observed in the 'overall' group												
rs12136063	1	110,014,170	SYPL2	A/G (0.70)	Intronic	0.0049	2.33E-07	0.0028	2.31E-02	0.0045	4.71E-08	0
rs2802729	1	243,501,763	SDCCAG8	A/C (0.43)	Intronic	-0.0050	7.37E-08	-0.0029	2.05E-02	-0.0046	2.20E-08	9
rs4667594	2	170,008,506	LRP2	A/T (0.53)	Intronic	-0.0045	2.37E-07	-0.0043	5.62E-02	-0.0044	3.52E-08	4
rs6795744 ^{††}	3	13,906,850	WNT7A	A/G (0.15)	Intronic	0.0071	9.60E-09	0.0019	5.15E-02	0.0060	3.33E-08	18
rs228611	4	103,561,709	NFKB1	A/G (0.47)	Intronic	-0.0055	4.66E-10	-0.0060	8.91E-04	-0.0056	3.38E-12	3
rs7759001	6	27,341,409	ZNF204	A/G (0.76)	ncRNA intronic	-0.0053	2.64E-07	-0.0045	9.10E-03	-0.0051	1.75E-08	0
rs10277115	7	1,285,195	UNCX	A/T (0.23)	Intergenic	0.0095	1.05E-10	0.0079	9.03E-04	0.0090	8.72E-14	0
rs3750082	7	32,919,927	KBTBD2	A/T (0.33)	Intronic	0.0049	2.52E-07	0.0031	1.96E-02	0.0045	3.22E-08	2
rs6459680	7	156,258,568	RNF32	T/G (0.74)	Intergenic	-0.0065	1.96E-10	-0.0019	4.62E-02	-0.0055	1.07E-09	0
rs4014195	11	65,506,822	AP5B1	C/G (0.64)	Intergenic	0.0061	2.19E-11	0.0034	1.42E-02	0.0055	1.10E-11	0
rs10491967	12	3,368,093	TSPAN9	A/G (0.10)	Intronic	-0.0092	3.03E-10	-0.0106	3.93E-04	-0.0095	5.18E-14	0
rs7956634	12	15,321,194	PTPRO	T/C (0.81)	Intronic	-0.0068	2.46E-09	-0.0069	1.51E-03	-0.0068	7.17E-12	0
rs1106766	12	57,809,456	INHBC	T/C (0.22)	Intergenic	0.0062	4.67E-08	0.0058	8.79E-03	0.0061	2.41E-09	9
rs11666497	19	38,464,262	SIPA1L3	T/C (0.18)	Intronic	-0.0064	8.58E-08	-0.0041	1.53E-02	-0.0058	4.25E-08	24
rs6088580	20	33,285,053	TP53NP2	C/G (0.47)	Intergenic	-0.0055	7.17E-10	-0.0027	2.31E-02	-0.0049	1.79E-09	0
rs17216707	20	52,732,362	BCAS1	T/C (0.79)	Intergenic	-0.0084	5.96E-13	-0.0051	6.69E-03	-0.0077	8.83E-15	1

bp, basepairs; Chr, chromosome; EAF, effect allele frequency; eGFRcrea, eGFR based on serum creatinine; GWAS, genome-wide association studies; SNP, single-nucleotide polymorphism; UTR, untranslated region.

*SNPs are grouped by the stratum where the smallest P value in the discovery and combined analysis was observed. In the 'no diabetes' group, sample size/number of studies were equal to 118,448/45, 36,433/13 and 154,881/58, in the discovery, replication and combined analyses, respectively. In the 'overall' group, the numbers for the three analyses were equal to 133,413/48, 42,116/14 and 175,579/62, respectively.

†On the basis of RefSeq genes (build 37).

‡Conventional locus name based on relevant genes in the region as identified by bioinformatic investigation (Supplementary Table 12) or closest gene. A complete overview of the genes in each locus is given in the regional association plots (Supplementary Fig. 4).

§SNP function is derived from NCBI RefSeq genes and may not correspond to the named gene.

||Twice genomic-control (GC) corrected P value from discovery GWAS meta-analysis: at the individual study level and after the meta-analysis.

#For random-effect estimate, see Supplementary Table 4.

#P value of the meta-analysis of the twice GC-corrected discovery meta-analysis results and replication studies.

**Between-study heterogeneity, as assessed by the I². Q statistic P value > 0.05 for all SNPs, except rs11666497 (SIPA1L3, P value = 0.04).

††For this SNP, the conditions for replication were not all met (q-value > 0.05 in the replication stage).

(Supplementary Fig. 7), suggesting that our findings can likely be generalized beyond the European ancestry group.

To identify additional potentially associated variants and more formally evaluate trans-ethnic heterogeneity of the loci identified through meta-analysis in European ancestry populations, we performed a trans-ethnic meta-analysis²², combining the 12 African ancestry studies with the 48 European Ancestry studies used in the discovery analysis of eGFRcrea. Of the 24 new loci uncovered for eGFRcrea, 15 were also genome-wide significant in the trans-ethnic meta-analysis (defined as log₁₀ Bayes Factor > 6, Supplementary Table 10), indicating that for most of these loci, there is little to no allelic effect heterogeneity across the two ethnic groups. No additional loci were significantly associated with log₁₀ Bayes Factor > 6.

Bioinformatic and functional characterization of new loci. We used several techniques to prioritize and characterize genes underlying the identified associations, uncover connections between associated regions, detect relevant tissues and assign functional annotations to associated variants. These included expression quantitative trait loci (eQTL) analyses, pathway analyses, DNase I hypersensitivity site (DHS) mapping, chromatin mapping, manual curation of genes in each region and zebrafish knockdown.

eQTL analysis. We performed eQTL analysis using publically available eQTL databases (see Methods). These analyses

connected novel SNPs to transcript abundance of *SYPL2*, *SDCCAG8*, *MANBA*, *KBTBD2*, *PTPRO* and *SPATA33* (*C16orf55*), thereby supporting these as potential candidate genes in the respective associated regions (Supplementary Table 11).

Pathway analyses. We used a novel method, Data-driven Expression Prioritized Integration for Complex Traits (DEPICT)²³, to prioritize genes at associated loci, to test whether genes at associated loci are highly expressed in specific tissues or cell types and to test whether specific biological pathways and gene sets are enriched for genes in associated loci. On the basis of all SNPs with eGFRcrea association P values < 10⁻⁵ in the discovery meta-analysis, representing 124 independent regions, we identified at least one significantly prioritized gene in 49 regions, including in 9 of the 24 novel genome-wide significant regions (Supplementary Table 12). Five tissue and cell type annotations were enriched for expression of genes from the associated regions, including the kidney and urinary tract, as well as hepatocytes and adrenal glands and cortex (Fig. 3a; Supplementary Table 13). Nineteen reconstituted gene sets showed enrichment of genes mapping into the associated regions at a permutation P value < 10⁻⁵ (Supplementary Table 14; Fig. 4), highlighting processes related to renal development, kidney transmembrane transporter activity, kidney and urogenital system morphology, regulation of glucose metabolism, as well as specific protein complexes important in renal development.




Figure 2 | Association eGFRcrea loci in subjects with and without diabetes. Novel (a) and known (b) loci were considered. Displayed are effects and their 95% confidence intervals on ln(eGFRcrea). Results are sorted by increasing effects in the diabetes group. The majority of loci demonstrated similar effect sizes in the diabetes as compared with non-diabetes strata. SNP-specific information and detailed sample sizes are reported in Supplementary Table 5.

DNase I hypersensitivity and H3K4m3 chromatin mark analyses.

To evaluate whether eGFRcrea-associated SNPs map into gene regulatory regions and to thereby gain insight into their potential function, we evaluated the overlap of independent eGFRcrea-associated SNPs with P values $< 10^{-4}$ (or their proxies) with DHSs using publicly available data from the Epigenomics Roadmap Project and ENCODE for 123 cell types (see Methods). DHSs mark accessible chromatin regions where transcription may occur. Compared with a set of control SNPs (see Methods), eGFRcrea-associated SNPs were significantly more likely to map to DHS in six specific tissues or cell types (Fig. 3b), including adult human renal cortical epithelial cells, adult renal proximal tubule epithelial cells, H7 embryonic stem cells (differentiated 2 days), adult human renal epithelial cells, adult small airway epithelial cells and amniotic epithelial cells. No significant enrichment was observed for adult renal glomerular endothelial cells, the only other kidney tissue evaluated.

Next, we analysed the overlap of the same set of SNPs with H3K4me3 chromatin marks, promoter-specific histone modifications associated with active transcription²⁴, in order to gather more information about cell-type specific regulatory potential of eGFRcrea-associated SNPs. Comparing 33 available adult-derived cell types, we found that eGFRcrea-associated SNPs showed the most significant overlap with H3K4me3 peaks in adult kidney (P value = 0.0029), followed by liver (P value = 0.0117), and rectal mucosa (P value = 0.0445). Taken together, these findings are suggestive of cell-type-specific regulatory roles for eGFR loci, with greatest specificity for the kidney.

Chromatin annotation maps.

In addition to assessing individual regulatory marks separately, we annotated the known and replicated novel SNPs, as well as their perfect proxies in a complementary approach. Chromatin annotation maps were generated integrating > 10 epigenetic marks from cells derived from adult human kidney tissue and a variety of non-renal tissues from the ENCODE project (see Methods). The proportion of variants to which a function could be assigned was significantly higher when using chromatin annotation maps from renal tissue compared with using maps that investigated the same epigenetic marks in other non-renal tissues (Fig. 3c), again indicating that eGFRcrea associated SNPs are, or tag, kidney-specific regulatory variants. The difference between kidney and non-renal tissues was particularly evident for marks that define enhancers: the proportion of SNPs mapping to weak and strong enhancer regions in the kidney tissue was higher than in all non-kidney tissues (Fishers' exact test P values from 3.1×10^{-3} to 7.9×10^{-6} , multiple testing threshold $\alpha = 5.6 \times 10^{-3}$).

Functional characterization of new loci.

To prioritize genes for functional studies, we applied gene prioritization algorithms including GRAIL²⁵, DEPICT and manual curation of selected genes in each region (Supplementary Table 12). For each region, gene selection criteria were as follows: (1) either GRAIL P value < 0.05 or DEPICT false discovery rate (FDR) < 0.05 ; (2) the effect of a given allele on eGFRcrea and on eGFRcys was direction-consistent and their ratio was between 0.2 and 5




Figure 3 | Bioinformatic analysis of eGFR-associated SNPs. Connection of eGFR-associated SNPs to gene expression and variant function across a variety of tissues, pathways and regulatory marks was considered. **(a)** The DEPICT method shows that implicated eGFR-associated genes are highly expressed in particular tissues, including kidney and urinary tract. Shown are permutation test P values (see Methods). **(b)** Enrichment of eGFRcrea-associated SNPs in DHS according to discovery P value threshold. SNPs from the eGFR discovery genome-wide scan meeting a series of P value thresholds in the range 10^{-4} – 10^{-16} preferentially map to DHSs, when compared with a set of control SNPs, in 6 of 123 cell types. Represented are main effects odds ratios from a logistic mixed effect model. Cell types indicated with coloured lines had nominally significant enrichment (* indicate P values < 0.05) at the P value $< 10^{-16}$ threshold and/or were derived from renal tissues (H7esDiffa2d: H7 embryonic stem cells, differentiated 2 days with BMP4, activin A and bFGF; Hae, amniotic epithelial cells; Hrcce, renal cortical epithelial cells; Hre, renal epithelial cells; Hrgec, renal glomerular endothelial cells; Rptec, renal proximal tubule epithelial cells; Saec, small airway epithelial cells). **(c)** ENCODE/Chromatin ChIP-seq mapping: known and replicated novel eGFRcrea-associated SNPs and their perfect proxies were annotated based on genomic location using chromatin annotation maps from different tissues including adult kidney epithelial cells. P values from Fisher's exact tests for 2×2 tables are reported (significance level = 5.6×10^{-3} , see Methods). There is significant enrichment of variants mapping to enhancer regions specifically in kidney but not other non-renal tissues.

(to ensure relative homogeneity of the beta coefficients); (3) nearest gene if the signal was located in a region containing a single gene. Using this approach, *NFKB1*, *DPEP1*, *TSPAN9*, *NFATC1*, *WNT7A*, *PTPRO*, *SYPL2*, *UNCX*, *KBTBD2*, *SKIL* and *AICF* were prioritized as likely genes underlying effects at the new loci (Supplementary Table 12).

We investigated the role of these genes during vertebrate kidney development by examining the functional consequences of gene knockdown in zebrafish embryos utilizing antisense morpholino oligonucleotide (MO) technology. After knockdown, we assessed the expression of established renal markers *pax2a* (global kidney), *nephrin* (podocytes) and *slc20a1a* (proximal tubule) at 48 hours post fertilization by *in situ* hybridization¹². In all cases, morphant embryos did not display significant gene expression defects compared with controls (Supplementary Table 15).

Discussion

We identified 24 new loci in association with eGFR and confirmed 29 previously identified loci. A variety of

complementary analytic, bioinformatic and functional approaches indicate enrichment of implicated gene products in kidney and urinary tract tissues. A greater proportion of the lead SNPs or their perfect proxies map into gene regulatory regions, specifically enhancers, in adult renal tissues compared with non-renal tissues. In addition to the importance in the adult kidney, our results indicate a role for kidney function variants during development.

We extend our previous findings, as well as those from other groups^{7–13} by identifying > 50 genomic loci for kidney function, many of which were not previously known to be connected to kidney function and disease. Using a discovery data set that is nearly double in size to our prior effort⁷, we are now able to robustly link associated SNPs to kidney-specific gene regulatory function. Our work further exemplifies the continued value of increasing the sample size of GWAS meta-analyses to uncover additional loci and gain novel insights into the mechanisms underlying common phenotypes²⁶.

There are several messages from our work. First, many of the genetic variants associated with eGFR appear to affect processes specifically within the kidney. The kidney is a highly vascular and




Figure 4 | Gene set overlap analysis. The 19 reconstituted gene sets with P value $< 10^{-5}$ were considered. Their overlap was estimated by computing the pairwise Pearson correlation coefficient ρ between each pair of gene sets followed by discretization into one of three bins: $0.3 \leq \rho < 0.5$, low overlap; $0.5 \leq \rho < 0.7$, medium overlap; $\rho \geq 0.7$, high overlap. Overlap is shown by edges between gene set nodes and edges representing overlap corresponding to $\rho < 0.3$ are not shown. The network was drawn with Cytoscape⁴⁸.

metabolically active organ that receives 20% of all cardiac output, contains an extensive endothelium-lined capillary network, and is sensitive to ischaemic and toxic injury. As a result, hypertension, cardiovascular diseases and diabetes each affect renal hemodynamics and contribute to kidney injury. However, many of the eGFR-associated SNPs in our GWAS could be assigned gene regulatory function specifically in the kidney and its epithelial cells, but not in human glomerular endothelial cells or the general vasculature. In addition, variants associated with eGFR were not associated with vascular traits, such as blood pressure or myocardial infarction. Taken together, these findings suggest that genetic determinants of eGFR may be mediated largely through direct effects within the kidney.

Second, despite the specificity related to renal processes, we also identified several SNPs that are associated with eGFR in diabetes, and our pathway analyses uncovered gene sets associated with glucose transporter activity and abnormal glucose homeostasis. Uncovering *bona fide* genetic loci for diabetic CKD has been difficult. We have now identified a total of 19 SNPs that demonstrate at least nominal association with eGFR in diabetes. The diabetes population is at particularly high risk of CKD, and identifying kidney injury pathways may help develop new treatments for diabetic CKD.

Finally, even though CKD is primarily a disease of the elderly, our pathway enrichment analyses highlight developmental processes relevant to the kidney and the urogenital tract. Kidney disease has been long thought to have developmental origins, in part related to early programming (Barker hypothesis)²⁷, low birth weight, nephron endowment and early growth and early-life nutrition²⁸. Our pathway enrichment analyses suggest that developmental pathways such as placental morphology, kidney weight and embryo size, as well as protein complexes of importance in renal development may in part contribute to the developmental origins of CKD.

A limitation of our work is that causal variants and precise molecular mechanisms underlying the observed associations were not identified and will require additional experimental follow-up projects. Our attempt to gain insights into potentially causal genes through knockdown in zebrafish did not yield any clear CKD candidate gene, although the absence of a zebrafish

phenotype upon gene knockdown does not mean that the gene cannot be the one underlying the observed association signal in humans. Finally, our conclusions that eGFR_{crea}-associated SNPs regulate the expression of nearby genes specifically in kidney epithelial cells are based on DHSs, H3K4me3 chromatin marks and chromatin annotation maps. Since these analyses rely mostly on variant positions, additional functional investigation such as luciferase assay that assess transcriptional activity more directly are likely to gain additional insights into the variants' mechanism of action.

The kidney specificity for loci we identified may have important translational implications, particularly since our DHS and chromatin annotation analyses suggest that at least a set of gene regulatory mechanisms is important in the adult kidney. Kidney-specific pathways are important for the development of novel therapies to prevent and treat CKD and its progression with minimal risk of toxicity to other organs. Finally, the biologic insights provided by these new loci may help elucidate novel mechanisms and pathways implicated not only in CKD but also of kidney function in the physiological range.

In conclusion, we have confirmed 29 genomic loci and identified 24 new loci in association with kidney function that together highlight target organ-specific regulatory mechanisms related to kidney function.

Methods

Overview. This was a collaborative meta-analysis with a distributive data model. Briefly, an analysis plan was created and circulated to all participating studies. Studies then uploaded study-specific data centrally; files were cleaned, and a specific meta-analysis for each trait was performed. Details regarding each step are provided below. All participants in all discovery and replication studies provided informed consent. Each study had its research protocol approved by the local ethics committee.

Phenotype definitions. Serum creatinine was measured in each discovery and replication study as described in Supplementary Tables 16 and 17, and statistically calibrated to the US nationally representative National Health and Nutrition Examination Study data in all studies to account for between-laboratory variation^{9,29,30}. eGFR_{crea} was estimated using the four-variable Modification of Diet in Renal Disease Study Equation. Cystatin C, an alternative biomarker for kidney function, was measured in a sub-set of participating studies. eGFR_{cys} was estimated as $76.7 \times (\text{serum cystatin C})^{-1.19}$ (ref. 31). eGFR_{crea} and eGFR_{cys} values

<15 ml min⁻¹ per 1.73 m² were set to 15, and those >200 were set to 200 ml min⁻¹ per 1.73 m². CKD was defined as eGFR_{crea} <60 ml min⁻¹ per 1.73 m².

Diabetes was defined as fasting glucose ≥126 mg dl⁻¹, pharmacologic treatment for diabetes or by self-report. In all studies, diabetes and kidney function were assessed at the same point in time.

Genotypes. Genotyping was conducted in each study as specified in Supplementary Tables 18 and 19. After applying appropriate quality filters, 45 studies used markers of highest quality to impute ~2.5 million SNPs, based on European-ancestry haplotype reference samples (HapMap II CEU). Four studies based their imputation on the 1000 Genomes Project data. Imputed genotypes were coded as the estimated number of copies of a specified allele (allelic dosage).

Genome-wide association analysis. By following a centralized analysis plan, each study regressed sex- and age-adjusted residuals of the logarithm of eGFR_{crea} or eGFR_{cys} on SNP dosage levels. Logistic regression of CKD status was performed on SNP dosage levels adjusting for sex and age. For all traits, adjustment for appropriate study-specific features, including study site and genetic principal components was included in the regression and family-based studies appropriately accounted for relatedness.

Stage 1 discovery meta-analysis. GWAS of eGFR_{crea} were contributed by 48 studies (total sample size, $N = 133,413$); 45 studies contributed GWAS data for the non-diabetes subgroup ($N = 118,448$) and 39 for the diabetes group ($N = 11,522$). GWAS of CKD were comprised by 43 studies, for a total sample size of 117,165, including 12,385 CKD cases. GWAS of eGFR_{cys} were comprised by 16 studies for a total sample size of 32,834. All GWAS files underwent quality control using the GWAtoolbox package³² in R, before including them into the meta-analysis. Genome-wide meta-analysis was performed with the software METAL³³, assuming fixed effects and using inverse-variance weighting. The genomic inflation factor λ was estimated for each study as the ratio between the median of all observed test statistics ($b/s.e.$)² and the expected median of a χ^2 with 1 degree of freedom, with b and $s.e.$ representing the effect of each SNP on the phenotype and its standard error, respectively³⁴. Genomic-control (GC) correction was applied to P values and $s.e.$'s in case of $\lambda > 1$ (first GC correction). SNPs with an average minor allele frequency (MAF) of ≥0.01 were used for the meta-analysis. To limit the possibility of false positives, after the meta-analysis, a second GC correction on the aggregated results was applied. Between-study heterogeneity was assessed through the I^2 statistic.

After removing SNPs with MAF of <0.05 and which were available in <50% of the studies, SNPs with a P value of ≤10⁻⁶ were selected and clustered into independent loci through LD pruning based on an r^2 of ≤0.2 within a window of ±1 MB to each side of the index SNP. After removing loci containing variants that have been previously replicated at a P value of 5.0 × 10⁻⁸ (refs 7,8), the SNP with the lowest P value within each locus was selected for replication ('index SNP'). If a SNP had an association P value of ≤10⁻⁶ with more than one trait, the trait where the SNP had the lowest P value was selected as discovery trait/stratum. Altogether, this resulted in 48 SNPs: 34 from eGFR_{crea}, 9 from eGFR_{crea} among those without diabetes, 4 from CKD and 1 from eGFR_{cys}.

Stage 2 replication analysis. *In silico* replication analysis for any of the studied traits was carried out using eight independent studies whose genotyping platforms are provided in Supplementary Table 19. *De novo* genotyping was performed in seven additional studies ($N = 22,850$ individuals) of European ancestry (Supplementary Table 20), including the Bus Santé, ESTHER, KORA-F3 (subset of F3 without GWAS), KORA-F4 (subset of F4 without GWAS), Ogliastra Genetic Park (OGP, without Talana whose GWAS was included in the discovery analysis), SAPHIR and SKIPOGH studies (Supplementary Table 20). Summarizing all *in silico* and *de novo* replication studies (Supplementary Table 1), replication data for eGFR_{crea} were contributed by 14 studies (total sample size = 42,166), which also contributed eGFR_{crea} results from non-diabetes (13 studies, $N = 36,433$) and diabetes samples (13 studies, $N = 4,955$). Thirteen studies contributed replication data on CKD ($N = 33,972$; 4,245 CKD cases; studies with <50 CKD cases were excluded) and five on eGFR_{cys} ($N = 14,930$).

Association between eGFR_{crea}, CKD and eGFR_{cys} and each of the 48 SNPs in the replication studies was assessed using the same analysis protocol detailed for the discovery studies above. Quality control of the replication files was performed with the same software as described above.

We performed a combined fixed-effect meta-analysis of the double-GC corrected results from the discovery meta-analysis and the replication studies, based on inverse-variance weighting. The total sample size in the combined analysis of eGFR_{crea} was 175,579 subjects (154,881 in the non-diabetes stratum and 16,477 in the diabetes stratum; the sum of these two sample sizes is smaller than the sample size of the overall analysis because some studies did not contribute both strata), 151,137 samples for CKD (16,630 CKD cases) and 47,764 for eGFR_{cys}. Three criteria were used to ensure validity of novel loci declared as significant: (1) P value from the combined meta-analysis ≤5.0 × 10⁻⁸ in accordance with previously published guidelines³⁵; (2) direction-consistent associations of the beta coefficients in stage 1 and stage 2 (one-sided P values were

estimated to test for consistent effect direction with the discovery stage); (3) q -value <0.05 in the replication stage. Q -values were estimated using the package QVALUE³⁶ in R. The tuning parameter lambda for the estimation of the overall proportion of true null hypotheses, π_0 , was estimated using the bootstrap method³⁷. When the third criterion was not satisfied, the locus was declared 'suggestive'.

Power analysis. With the sample size achieved in the combined analysis of stage 1 and stage 2 data, the power to assess replication at the canonical genome-wide significance level of 5.0 × 10⁻⁸ was estimated with the software QUANTO³⁸ version 1.2.4, assuming the same MAF and effect size observed in the discovery sample. Power to replicate associations ranged from 87 to 100% for eGFR_{crea} associated SNPs (median = 98%), from 72 to 96% for the CKD-associated SNPs, and was equal to 59% for the eGFR_{cys}-associated SNP (Supplementary Table 3).

Associations stratified by diabetes and hypertension status. For all the 24 novel and 29 known SNPs, the difference between the SNP effect on eGFR_{crea} in the diabetes versus the non-diabetes groups was assessed by means of a two-sample t -test for correlated data at a significance level of 0.05. We used the following two-sample t -test for correlated data:

$$t = \frac{(b_{DM} - b_{nonDM})}{\left\{s.e.(b_{DM})^2 + s.e.(b_{nonDM})^2 - 2 \times \rho(b_{DM}, b_{nonDM}) \times s.e.(b_{DM}) \times s.e.(b_{nonDM})\right\}^{0.5}}$$

where b_{DM} and b_{nonDM} represent the SNP effects on log(eGFR_{crea}) in the two groups, $s.e.$ is the standard error of the estimate and $\rho(.)$ indicates the correlation between effects in the two groups, which was estimated as 0.044 by sampling 100,000 independent SNPs from our DM and nonDM GWAS, after removing known and novel loci associated with eGFR_{crea}. For a large sample size, as in our case, t follows a standard normal distribution.

A similar analysis was performed to compare results in subjects with and without hypertension, based on results from our previous work⁷. The correlation between the two strata was of 0.01.

Proportion of phenotypic variance explained. The percent of phenotypic

variance explained by novel and known loci was estimated as $\sum_{i=1}^{53} R_i^2$, where

$R_i^2 = b_i^2 \text{var}(\text{SNP}_i) / \text{var}(y)$ is the coefficient of determination for each of the 53 individual SNPs associated with eGFR_{crea} uncovered to date (24 novel and 29 known ones), b_i is the estimated effect of the i^{th} SNP on y , y corresponds to the sex- and age-adjusted residuals of the logarithm of eGFR_{crea} and $\text{var}(\text{SNP}_i) = 2 \times \text{MAF}_{\text{SNP}_i} \times (1 - \text{MAF}_{\text{SNP}_i})$ ³⁹. $\text{var}(y)$ was estimated in the ARIC study and all loci were assumed to have independent effects on the phenotype.

Test for SNP associations with related traits. We performed evaluations of SNP association with results generated from consortia investigating other traits. Specifically, we evaluated systolic and diastolic blood pressure in ICBP¹⁷, myocardial infarction in CARDIOGRAM¹⁸, left ventricular mass¹⁹, heart failure²⁰, the urinary albumin to creatinine ratio (CKDGen consortium, personal communication) and fasting plasma glucose in MAGIC²¹. In total, we performed 165 tests, corresponding to 7 traits tested for association against each of the 24 novel SNP, with the exception of myocardial infarction for which results from 3 SNPs were not available (Supplementary Table 6). Significance was evaluated at the Bonferroni corrected level of 0.05/165 = 0.0003.

Lookup of replicated loci in the NHGRI GWAS catalog. All replicated SNPs, as well as SNPs in LD ($r^2 > 0.2$) within ±1 MB distance were checked for their association with other traits according to the NHGRI GWAS catalog⁴⁰ (accessed April 14, 2014).

SNP assessments in other ethnic groups. We performed cross-ethnicity SNP evaluations in participants of African ancestry from a meta-analysis of African ancestry individuals and from participants of Asian descent from the AGEN consortium¹¹.

African ancestry meta-analysis. We performed fixed-effect meta-analysis of the genome-wide association data from 12 African ancestry studies (Supplementary Table 8) with imputation to HapMap reference panel, based on inverse-variance weighting using METAL. Only SNPs with MAF ≥0.01 and imputation quality $r^2 \geq 0.3$ were considered for the meta-analysis. After meta-analysis, we removed SNPs with MAF <0.05 and which were available in <50% of the studies. Statistical significance was assessed at the standard threshold of 5.0 × 10⁻⁸. Genomic control correction was applied at both the individual study level before meta-analysis and after the meta-analysis.

Transethnic meta-analysis. We performed a trans-ethnic meta-analysis of GWAS data from cohorts of different ethnic backgrounds using MANTRA (Meta-Analysis

of Trans-ethnic Association studies) software²². We combined the 48 European ancestry studies that contributed eGFRcrea, which were included in stage 1 discovery meta-analysis, and the 12 African ancestry studies mentioned above for a total sample size of 150,253 samples. We limited our analysis to biallelic SNPs with MAF ≥ 0.01 and imputation quality $r^2 \geq 0.3$. Relatedness between the 60 studies was estimated using default settings from up to 5.9 million SNPs. Only SNPs that were present in more than 25 European ancestry studies and 6 African ancestry studies (total sample size $\geq 120,000$) were considered after meta-analysis. Genome-wide significance was defined as a \log_{10} Bayes' Factor ($\log_{10}BF$) ≥ 6 (ref. 41).

Gene Relationships Across Implicated Loci (GRAIL). To prioritize the gene(s) most likely to give rise to association signals in a given region, the software GRAIL was used²⁵. The index SNP of all previously known kidney function associated regions, as well as the novel SNPs identified here was used as input, using the CEU HapMap (hg18 assembly) and the functional datasource text_2009_03, established before the publication of kidney function-related GWAS. Results from GRAIL were used to prioritize genes for follow-up functional work.

Expression quantitative trait loci analysis. We identified alias rsIDs and proxies ($r^2 > 0.8$) for our index SNPs using SNP software across 4 HapMap builds. SNP rsIDs and aliases were searched for primary SNPs and LD proxies against a collected database of expression SNP (eSNP) results. The collected eSNP results met criteria for statistical thresholds for association with gene transcript levels in their respective original analyses (for references see Supplementary Table 11). Correlation of selected eSNPs to the best eSNPs per transcript per expression quantitative trait loci (eQTL) data set were assessed by pairwise LD. All results are reported in Supplementary Table 11.

DEPICT analysis. In this work, we first used PLINK⁴² to identify independently associated SNPs using all SNPs with eGFRcrea association P values $< 10^{-5}$ (HapMap release 27 CEU data⁴³; LD r^2 threshold = 0.01; physical kb threshold = 1,000). We then used the DEPICT method²³ to construct associated regions by mapping genes to independently associated SNPs if they overlapped or resided within LD ($r^2 > 0.5$) distance of a given associated SNP. After merging overlapping regions and discarding regions that mapped within the major histocompatibility complex locus (chromosome 6, base pairs 20,000,000–40,000,000), 124 non-overlapping regions remained that covered a total of 320 genes. Finally, we ran the DEPICT software program on the 124 regions to prioritize genes that may represent promising candidates for experimental follow up studies, identify reconstituted gene sets that are enriched in genes from associated regions and therefore may provide insight into general kidney function biology, and identify tissue and cell-type annotations in which genes from associated regions are highly expressed. Specifically, for each tissue, the DEPICT method performs a t -test comparing the tissue-specific expression of eGFRcrea-associated genes and all other genes. Next, for each tissue, empirical enrichment P values are computed by repeatedly sampling random sets of loci (matched to the actual eGFRcrea loci by gene density) from the entire genome to estimate the empirical mean and s.d. of the enrichment statistic's null distribution. To visualize the nineteen reconstituted gene sets with P value $< 1e-5$ (Fig. 4), we estimated their overlap by computing the pairwise Pearson correlation coefficient ρ between each pair of gene sets followed by discretization into one of three bins; $0.3 \leq \rho < 0.5$, low overlap; $0.5 \leq \rho < 0.7$, medium overlap; $\rho \geq 0.7$, high overlap.

DNase I hypersensitivity analysis. The overlap of SNPs associated with eGFRcrea at $P < 10^{-4}$ with DHSs was examined using publicly available data from the Epigenomics Roadmap Project and ENCODE. In all, DHS mappings were available for 123 mostly adult cells and tissues⁴⁴ (downloaded from <http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeUwDnase/>). The analysis here pertains to DHS's defined as "broad" peaks, which were available as experimental replicates (typically duplicates) for the majority of cells and tissues.

SNPs from our stage 1 eGFRcrea GWAS meta-analysis were first clumped in PLINK⁴² in windows of 100 kb and maximum r^2 of 0.1 using LD relationships from the 1,000 Genomes EUR panel (phase I, v3, 3/14/2012 haplotypes) using a series of P value thresholds (10^{-4} , 10^{-6} , 10^{-8} , ... and 10^{-16}). LD proxies of the index SNPs from the clumping procedure were then identified by LD tagging in PLINK with $r^2 = 0.8$ in windows of 100 kb, again using LD relationships in the 1000G EUR panel, restricted to SNPs with MAF $> 1\%$ and also present in the HapMap2 CEU population. A reference set of control SNPs was constructed using the same clumping and tagging procedures applied to NHGRI GWAS catalog SNPs (available at <http://www.genome.gov/gwastudies/>, accessed 13 March 2013) with discovery P values $< 5.0 \times 10^{-8}$ in European populations. In total, there were 1,204 such reference SNPs after LD pruning. A small number of reference SNPs or their proxies overlapping with the eGFRcrea SNPs or their proxies were excluded. For each cell-type and P value threshold, the enrichment of eGFR SNPs (or their LD proxies) mapping to DHSs relative to the GWAS catalog reference SNPs (or their LD proxies) was expressed as an odds ratio from logistic mixed effect models that treated the replicate peak determinations as random effects (lme4 package in R). Significance for enrichment odds ratio was derived from the significance of beta coefficients for the main effects in the mixed models.

Interrogation of human kidney chromatin annotation maps. Different chromatin modification patterns can be used to generate tissue-specific chromatin-state annotation maps. These can serve as a valuable resource to discover regulatory regions and study their cell-type-specific distributions and activities, which may help with the interpretation especially of intergenic variants identified in association studies⁴⁵. We therefore investigated the genomic mapping of the known and replicated novel index SNPs, as well as their perfect LD proxies ($n = 173$, $r^2 = 1$ for proxies) using a variety of resources, including chromatin maps generated from human kidney tissue cells (HKC-E cells). Chromatin immune-precipitation sequencing (ChIP-seq) data from human kidney samples were generated by NIH Roadmap Epigenomics Mapping Consortium⁴⁶. Briefly, proximal tubule cells derived from an adult human kidney were collected and cross-linked with 1% formaldehyde. Subsequently, ChIP-seq was conducted using whole-cell extract from adult kidney tissue as the input (GSM621638) and assessing the following chromatin marks: H3K36me3 (GSM621634), H3K4me1 (GSM670025), H3K4me3 (GSM621648), H3K9ac (GSM772811) and H3K9me3 (GSM621651). The MACS version 1.4.1 (model-based analysis of ChIP-Seq) peak-finding algorithm was used to identify regions of ChIP-Seq enrichment⁴⁷. A FDR threshold of enrichment of 0.01 was used for all data sets. The resulting genomic coordinates in bed format were further used in ChromHMM v1.06 for chromatin annotation⁴⁵. For comparison, the same genomic coordinates were investigated in chromatin annotation maps of renal tissue, as well as across nine different cell lines from the ENCODE Project: umbilical vein endothelial cells (HUVEC), mammary epithelial cells (HMEC), normal epidermal keratinocytes (NHEK), B-lymphoblastoid cells (GM12878), erythrocytic leukemia cells (K562), normal lung fibroblasts (NHLF), skeletal muscle myoblasts (HSM), embryonic stem cells (H1 ES) and hepatocellular carcinoma cells (HepG2). We tested whether the proportion of SNPs pointing to either strong or weak enhancers in the human kidney tissue cells was different from that of the other nine tissues by means of a Fishers' exact test for 2×2 tables, contrasting each of the nine cell lines listed above against the reference kidney cell line, at a Bonferroni-corrected significance level of $0.05/9 = 5.6 \times 10^{-3}$.

Functional characterization of new loci. Replicated gene regions were prioritized for functional studies using the following criteria: (1) GRAIL identification of a gene in each region of P value < 0.05 or DEPICT, FDR < 0.05 ; (2) an eGFRcrea to eGFRcys ratio between 0.2 and 5 with direction consistency between the beta coefficients; (3) nearest gene if the signal was located in a gene-poor region. The list of genes selected for functional work can be found in Supplementary Table 12. This same prioritization scheme was also used to assign locus names. Morpholino knockdowns were performed in zebrafish.

Zebrafish (strain Tübingen, TU) were maintained according to established Harvard Medical School Institutional Animal Care and Use Committee protocols (protocol # 04626). Male and female fish were mated (age 6–12 months) for embryo production. Embryos were injected at the one-cell stage with MOs (GeneTools) designed to block either the ATG start site or an exon–intron splice site of the target gene (Supplementary Table 21). In cases where human loci are duplicated in zebrafish, both orthologues were knocked down simultaneously by combination MO injection. MOs were injected in escalating doses at concentrations up to 250 μ M. Embryos were fixed in 4% paraformaldehyde at 48 h post fertilization for *in situ* hybridization using published methods (<http://zfin.org/ZFIN/Methods/ThisseProtocol.html>). Gene expression was visualized using established renal markers *pax2a* (global kidney), *nephrin* (podocytes) and *slc20a1a* (proximal tubule). The number of morphant embryos displaying abnormal gene expression was compared with control embryos by means of a Fisher's exact test.

References

- Eckardt, K. U. *et al.* Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet* **382**, 158–169 (2013).
- El Nahas, M. The global challenge of chronic kidney disease. *Kidney Int.* **68**, 2918–2929 (2005).
- Baumeister, S. E. *et al.* Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population. *Am. J. Nephrol.* **31**, 222–229 (2010).
- Fox, C. S. *et al.* Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* **380**, 1662–1673 (2012).
- Mahmoodi, B. K. *et al.* Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *Lancet* **380**, 1649–1661 (2012).
- Himmelfarb, J. & Tuttle, K. R. New therapies for diabetic kidney disease. *N. Engl. J. Med.* **369**, 2549–2550 (2013).
- Pattaro, C. *et al.* Genome-wide association and functional follow-up reveals new loci for kidney function. *PLoS Genet.* **8**, e1002584 (2012).
- Kottgen, A. *et al.* New loci associated with kidney function and chronic kidney disease. *Nat. Genet.* **42**, 376–384 (2010).
- Kottgen, A. *et al.* Multiple loci associated with indices of renal function and chronic kidney disease. *Nat. Genet.* **41**, 712–717 (2009).
- Chambers, J. C. *et al.* Genetic loci influencing kidney function and chronic kidney disease. *Nat. Genet.* **42**, 373–375 (2010).

11. Okada, Y. *et al.* Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. *Nat. Genet.* **44**, 904–909 (2012).
12. Liu, C. T. *et al.* Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. *PLoS Genet.* **7**, e1002264 (2011).
13. Boger, C. A. *et al.* Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. *PLoS Genet.* **7**, e1002292 (2011).
14. Chasman, D. I. *et al.* Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. *Hum. Mol. Genet.* **21**, 5329–5343 (2012).
15. Pattaro, C. *et al.* A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level. *BMC Med. Genet.* **11**, 41 (2010).
16. Trudu, M. *et al.* Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat. Med.* **19**, 1655–1660 (2013).
17. International Consortium for Blood Pressure Genome-Wide Association Studies *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* **478**, 103–109 (2011).
18. Schunkert, H. *et al.* Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat. Genet.* **43**, 333–338 (2011).
19. Vasan, R. S. *et al.* Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. *JAMA* **302**, 168–178 (2009).
20. Smith, N. L. *et al.* Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. *Circ. Cardiovasc. Genet.* **3**, 256–266 (2010).
21. Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
22. Morris, A. P. Transethnic meta-analysis of genomewide association studies. *Genet. Epidemiol.* **35**, 809–822 (2011).
23. Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using predicted gene functions. *Nat. Commun.* **6**, 5890 (2015).
24. Trynka, G. *et al.* Chromatin marks identify critical cell types for fine mapping complex trait variants. *Nat. Genet.* **45**, 124–130 (2013).
25. Raychaudhuri, S. *et al.* Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet.* **5**, e1000534 (2009).
26. Panagiotou, O. A., Willer, C. J., Hirschhorn, J. N. & Ioannidis, J. P. The power of meta-analysis in genome-wide association studies. *Annu. Rev. Genomics Hum. Genet.* **14**, 441–465 (2013).
27. Barker, D. J. The fetal and infant origins of adult disease. *BMJ* **301**, 1111 (1990).
28. Boubred, F. *et al.* Developmental origins of chronic renal disease: an integrative hypothesis. *Int. J. Nephrol.* **2013**, 346067 (2013).
29. Fox, C. S. *et al.* Predictors of new-onset kidney disease in a community-based population. *JAMA* **291**, 844–850 (2004).
30. Coresh, J. *et al.* Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am. J. Kidney Dis.* **39**, 920–929 (2002).
31. Stevens, L. A. *et al.* Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am. J. Kidney Dis.* **51**, 395–406 (2008).
32. Fuchsberger, C., Taliun, D., Pramstaller, P. P. & Pattaro, C. CKDgen consortium. GWAToolbox: an R package for fast quality control and handling of GWAS meta-analysis data. *Bioinformatics* **28**, 444–445 (2012).
33. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
34. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).
35. Skol, A. D., Scott, L. J., Abecasis, G. R. & Boehnke, M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat. Genet.* **38**, 209–213 (2006).
36. Storey, J. D. A direct approach to false discovery rates. *J. R. Stat. Soc. B* **64**, 479–498 (2002).
37. Storey, J. D., Taylor, J. E. & Siegmund, D. Strong control, conservative point estimation, and simultaneous conservative consistency of false discovery rates: a unified approach. *J. R. Stat. Soc. B* **66**, 187–205 (2004).
38. Gauderman, W. J. Sample size requirements for matched case-control studies of gene-environment interaction. *Stat. Med.* **21**, 35–50 (2002).
39. Rosner, B. in *Fundamentals of Biostatistics* (Thomson-Brooks/Cole, Duxbury, 2006).
40. Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* **42**, D1001–D1006 (2014).
41. Wang, X. *et al.* Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies. *Hum. Mol. Genet.* **22**, 2303–2311 (2013).
42. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
43. International HapMap Consortium. The International HapMap Project. *Nature* **426**, 789–796 (2003).
44. Maurano, M. T. *et al.* Systematic localization of common disease-associated variation in regulatory DNA. *Science* **337**, 1190–1195 (2012).
45. ENCODE Project Consortium *et al.* An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012).
46. Ko, Y. A. *et al.* Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. *Genome Biol.* **14**, R108 (2013).
47. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).
48. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 (2003).

Acknowledgements

Study-specific acknowledgements and funding sources for participating studies are reported in Supplementary Note. Zebrafish work was supported by NIH R01DK090311 and R24OD017870 to W.G.

Author contributions

Study design: C Helmer, B Stengel, J Chalmers, M Woodward, P Hamet, G Eiriksdottir, LJ Launer, TB Harris, V Gudnason, JR O’Connell, A Köttgen, E Boerwinkle, WHL Kao, P Mitchell, I Guessous, JM Gaspoz, N Bouatia-Naji, P Froguel, A Metspalu, T Esko, BA Oostra, CM van Duijn, V Emilsson, H Brenner, I Borecki, CS Fox, Q Yang, BK Krämer, PS Wild, BI Freedman, J Ding, Y Liu, AB Zonderman, MK Evans, A Adeyemo, CN Rotimi, D Cusi, P Gasparini, M Ciullo, D Toniolo, C Gieger, C Meisinger, CA Böger, HE Wichmann, T Illig, I Rudan, W März, PP Pramstaller, EP Bottinger, BW Penninx, H Snieder, U Gyllensten, AF Wright, H Campbell, JF Wilson, SH Wild, GJ Navis, BM Buckley, I Ford, JW Jukema, B Paulweber, L Kedenko, F Kronenberg, K Endlich, R Rettig, R Biffar, H Völzke, JK Fernandes, MM Sale, M Pruijm, GB Ehret, A Tönjes, M Stumvoll, JC Denny, RJ Carroll, N Hastie, O Polasek, PM Ridker, J Viikari, M Kähönen, O Raitakari, T Lehtimäki.

Study management: C Helmer, M Metzger, J Tremblay, J Chalmers, M Woodward, P Hamet, G Eiriksdottir, TB Harris, T Aspelund, V Gudnason, A Parsa, AR Shuldiner, BD Mitchell, E Boerwinkle, J Coresh, WHL Kao, R Schmidt, L Ferrucci, E Rohtchina, JJ Wang, J Attia, P Mitchell, I Guessous, JM Gaspoz, M Bochud, DS Siscovick, O Devuyst, P Froguel, T Esko, BA Oostra, CM van Duijn, V Emilsson, DK Dieffenbach, H Brenner, I Borecki, CS Fox, M Rheinberger, ST Turner, S Kloiber, PS Wild, J Ding, Y Liu, SLR Kardia, AB Zonderman, MK Evans, MC Cornelis, A Adeyemo, CN Rotimi, D Cusi, E Salvi, PB Munroe, P Gasparini, M Ciullo, R Sorice, C Sala, D Toniolo, AW Dreisbach, DI Chasman, C Gieger, C Meisinger, M Waldenberger, HE Wichmann, T Illig, W Koenig, I Rudan, I Kolcic, M Boban, T Zemunik, W März, H Kramer, PP Pramstaller, EP Bottinger, O Gottesman, BW Penninx, H Snieder, JH Smit, AF Wright, H Campbell, JF Wilson, SH Wild, W Lieb, GJ Navis, BM Buckley, I Ford, JW Jukema, A Hofman, OH Franco, M Adam, M Imboden, N Probst-Hensch, B Paulweber, L Kedenko, F Kronenberg, S Coassin, M Haun, HK Kroemer, K Endlich, M Nauck, R Rettig, R Biffar, S Stracke, U Völker, H Wallaschofski, H Völzke, KL Keene, MM Sale, B Ponte, D Ackermann, M Pruijm, GB Ehret, A Tönjes, P Kovacs, JC Denny, RJ Carroll, C Hayward, O Polasek, V Vitart, PM Ridker, J Viikari, M Kähönen, O Raitakari, T Lehtimäki.

Subject recruitment: C Helmer, P Hamet, TB Harris, T Aspelund, V Gudnason, AR Shuldiner, BD Mitchell, J Coresh, WHL Kao, M Cavaliere, R Schmidt, JB Whitfield, NG Martin, L Ferrucci, P Mitchell, I Guessous, DS Siscovick, O Devuyst, A Metspalu, BA Oostra, CM van Duijn, BK Krämer, ST Turner, S Kloiber, PS Wild, BI Freedman, MA McEvoy, RJ Scott, AB Zonderman, MK Evans, GC Curhan, A Adeyemo, CN Rotimi, D Cusi, A Lupo, G Gambaro, P d’Adamo, A Robino, S Ulivi, D Ruggiero, M Ciullo, R Sorice, D Toniolo, C Gieger, C Meisinger, CA Böger, HE Wichmann, T Illig, W Koenig, I Rudan, I Kolcic, M Boban, T Zemunik, PP Pramstaller, EP Bottinger, BW Penninx, Å Johansson, I Persico, M Pirastu, JF Wilson, SH Wild, A Franke, G Jacobs, GJ Navis, IM Leach, BM Buckley, I Ford, JW Jukema, N Probst-Hensch, B Paulweber, L Kedenko, F Kronenberg, R Rettig, R Biffar, S Stracke, H Völzke, P Muntner, JK Fernandes, MM Sale, B Ponte, D Ackermann, M Pruijm, GB Ehret, A Tönjes, JC Denny, RJ Carroll, O Polasek, J Viikari, M Kähönen, O Raitakari, T Lehtimäki.

Interpretation of results: C Helmer, JC Lambert, M Metzger, B Stengel, V Chouraki, J Tremblay, J Chalmers, M Woodward, P Hamet, AV Smith, A Parsa, JR O’Connell, A Tin, A Köttgen, M Li, WHL Kao, Y Li, EG Holliday, J Attia, I Guessous, CA Peralta, AC Morrison, JF Felix, C Pattaro, G Li, IH de Boer, O Devuyst, H Lin, A Isaacs, V Emilsson, AD Johnson, CS Fox, M Olden, Q Yang, EJ Atkinson, M de Andrade, ST Turner, T Zeller, J Ding, Y Liu, M Nalls, A Adeyemo, D Shriner, D Cusi, E Salvi, V Mijatovic, D Ruggiero, R Sorice, AW Dreisbach, AY Chu, DI Chasman, CA Böger, IM Heid, M Gorski, B Tayo, C Fuchsberger, H Snieder, IM Nolte, W Igl, K Suszkat,

N Verweij, S Trompet, A Dehghan, B Kollerits, F Kronenberg, A Teumer, J Divers, KL Keene, MM Sale, WM Chen, GB Ehret, I Prokopenko, R Mägi, JC Denny, RJ Carroll.

Design, performance and interpretation of zebrafish experiments: M Garnaas, W Goessling.

Drafting manuscript: J Chalmers, A Tin, A Köttgen, WHL Kao, M Bochud, CA Peralta, C Pattaro, IH de Boer, CS Fox, M Garnaas, W Goessling, N Soranzo, CA Böger, IM Heid, M Gorski, S Trompet, A Dehghan, A Teumer, KL Keene, MM Sale.

Critical review of the manuscript: J Tremblay, J Chalmers, M Woodward, P Hamet, TB Harris, V Gudnason, A Parsa, AR Shuldiner, BD Mitchell, A Tin, A Köttgen, E Boerwinkle, J Coresh, M Li, WHL Kao, Y Li, H Schmidt, M Cavaliere, R Schmidt, JB Whitfield, EG Holliday, JJ Wang, J Attia, P Mitchell, I Guessous, JM Gaspoz, M Bochud, CA Peralta, AC Morrison, JF Felix, C Pattaro, DS Siscovick, IH de Boer, M Rao, R Katz, O Devuyt, TH Pers, A Isaacs, H Brenner, M Garnaas, W Goessling, BK Krämer, M Rheinberger, ST Turner, D Czamara, S Kloiber, T Zeller, BI Freedman, JM Stafford, J Ding, Y Liu, MA McEvoy, RJ Scott, SJ Hancock, JA Smith, JD Faul, SLR Kardina, AB Zonderman, M Nalls, MK Evans, FB Hu, GC Curhan, MC Cornelis, A Lupo, G Gambaro, G Malerba, M Ciullo, R Sorice, AW Dreisbach, AY Chu, DI Chasman, C Gieger, H Grallert, C Meisinger, M Waldenberger, CA Böger, HE Wichmann, IM Heid, M Gorski, T Illig, W Koenig, I Kolcic, M Boban, T Zemunik, O März, B Tayo, H Kramer, SE Rosas, C Fuchsberger, D Ruderfer, EP Bottinger, O Gottesman, RJF Loos, Y Lu, H Snieder, H Campbell, A Franke, W Lieb, IM Leach, BM Buckley, I Ford, JW Jukema, S Trompet, A Dehghan, S Sedaghat, GA Thun, M Adam, M Imboden, N Probst-Hensch, B Kollerits, B Paulweber, L Kedenko, F Kronenberg, A Teumer, K Endlich, H Völzke, KL Keene, MM Sale, WM Chen, B Ponte, D Ackermann, M Pruijm, GB Ehret, A Tönjes, I Prokopenko, M Stumvoll, P Kovacs, R Mägi, JC Denny, O Polasek, J Viikari, LP Lyytikäinen, M Kähönen, O Raitakari, T Lehtimäki.

Statistical methods and analysis: C Helmer, JC Lambert, M Metzger, V Chouraki, J Tremblay, P Hamet, AV Smith, T Aspelund, A Parsa, JR O'Connell, A Tin, A Köttgen, M Li, M Foster, WHL Kao, Y Li, H Schmidt, M Struchalin, NG Martin, RPS Middelberg, T Tanaka, E Rohtchina, EG Holliday, I Guessous, M Bochud, JF Felix, C Pattaro, G Li, R Katz, JN Hirschhorn, J Karjalainen, L Franke, TH Pers, L Yengo, N Bouatia-Naji, H Lin, T Nikopensius, T Esko, A Isaacs, A Demirkan, MF Feitosa, M Olden, MH Chen, Q Yang, SJ Hwang, M Garnaas, W Goessling, EJ Atkinson, M de Andrade, D Czamara, S Kloiber, C Müller, JM Stafford, J Ding, K Lohman, Y Liu, JA Smith, JD Faul, M Nalls, MC Cornelis, A Adeyemo, D Shriner, E Salvi, V Mijatovic, A Robino, S Ulivi, R Sorice, G Pistis, M Cocca, AY Chu, DI Chasman, LM Rose, CA Böger, IM Heid, M Gorski, ME Kleber, B Tayo, C Fuchsberger, A Saint-Pierre, D Taliun, D Ruderfer, Y Lu, IM Nolte, PJ van der Most, S Enroth, W Igl, F Murgia, L Portas, K Susztak, YA Ko, N Verweij, S Trompet, A Dehghan, S Sedaghat, GA Thun, M Adam, M Imboden, N Probst-Hensch, B Kollerits, A Teumer, J Divers, WM Chen, GB Ehret, I Prokopenko, R Mägi, CM Shaffer, RJ Carroll, C Hayward, V Vitart, LP Lyytikäinen, V Aalto.

Genotyping: JC Lambert, J Tremblay, P Hamet, E Boerwinkle, WHL Kao, H Schmidt, GW Montgomery, L Ferrucci, M Bochud, BA Oostra, CM van Duijn, K Butterbach, I Borecki, M de Andrade, T Zeller, Y Liu, RJ Scott, SLR Kardina, M Nalls, FB Hu, GC Curhan, A Adeyemo, D Shriner, D Cusi, N Soranzo, P d'Adamo, D Ruggiero, M Ciullo, R Sorice, DI Chasman, H Grallert, T Zemunik, ME Kleber, EP Bottinger, O Gottesman, RJF Loos, AF Wright, JF Wilson, A Franke, D Ellinghaus, JW Jukema, S Trompet, AG Uitterlinden, F Rivadeneira, F Kronenberg, S Coassin, M Haun, F Ernst, G Homuth, HK Kroemer, M Nauck, U Völker, H Wallaschofski, MM Sale, GB Ehret, A Tönjes, M Stumvoll, P Kovacs, CM Shaffer, JC Denny, PM Ridker, T Lehtimäki.

Bioinformatics: JC Lambert, V Chouraki, J Tremblay, P Hamet, AV Smith, T Aspelund, JR O'Connell, E Boerwinkle, Y Li, M Struchalin, GW Montgomery, RPS Middelberg, T Tanaka, C Pattaro, G Li, JN Hirschhorn, J Karjalainen, L Franke, TH Pers, L Yengo, T Esko, AD Johnson, M Olden, M Garnaas, W Goessling, D Czamara, C Müller, JA Smith, SLR Kardina, M Nalls, E Salvi, G Malerba, V Mijatovic, P d'Adamo, S Ulivi, R Sorice, C Sala, G Pistis, M Cocca, DI Chasman, H Grallert, M Waldenberger, CA Böger, IM Heid, M Gorski, ME Kleber, D Taliun, O Gottesman, S Enroth, K Susztak, YA Ko, D Ellinghaus, N Verweij, I Ford, S Trompet, F Rivadeneira, WM Chen, GB Ehret, R Mägi, CM Shaffer, JC Denny, RJ Carroll, C Hayward, LP Lyytikäinen, V Aalto.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: J.T. and P.H. are consultants for Servier. J.C. received research grants and honoraria from Servier. K.S. obtained research support from Boehringer Ingelheim. The remaining authors declared no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Pattaro, C. *et al.* Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat. Commun.* 7:10023 doi: 10.1038/ncomms10023 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Cristian Pattaro^{1,*}, Alexander Teumer^{2,3,*}, Mathias Gorski^{4,5,*}, Audrey Y. Chu^{6,*}, Man Li^{7,*}, Vladan Mijatovic^{8,*}, Maija Garnaas⁹, Adrienne Tin⁷, Rossella Sorice¹⁰, Yong Li¹¹, Daniel Taliun¹, Matthias Olden^{4,5}, Meredith Foster¹², Qiong Yang¹³, Ming-Huei Chen^{13,14}, Tune H. Pers^{15,16}, Andrew D. Johnson¹⁷, Yi-An Ko¹⁸, Christian Fuchsberger¹, Bamidele Tayo¹⁹, Michael Nalls²⁰, Mary F. Feitosa²¹, Aaron Isaacs^{22,23}, Abbas Dehghan²⁴, Pio d'Adamo²⁵, Adebawale Adeyemo²⁶, Aida Karina Dieffenbach^{27,28}, Alan B. Zonderman²⁹, Ilja M. Nolte³⁰, Peter J. van der Most³⁰, Alan F. Wright³¹, Alan R. Shuldiner^{32,33}, Alanna C. Morrison³⁴, Albert Hofman²⁴, Albert V. Smith^{35,36}, Albert W. Dreisbach³⁷, Andre Franke³⁸, Andre G. Uitterlinden³⁹, Andres Metspalu^{40,41}, Anke Tonjes⁴², Antonio Lupo⁴³, Antonietta Robino²⁵, Åsa Johansson⁴⁴, Ayse Demirkan²², Barbara Kollerits⁴⁵, Barry I. Freedman⁴⁶, Belen Ponte⁴⁷, Ben A. Oostra⁴⁸, Bernhard Paulweber⁴⁹, Bernhard K. Krämer⁵⁰, Braxton D. Mitchell^{32,33}, Brendan M. Buckley⁵¹, Carmen A. Peralta⁵², Caroline Hayward³¹, Catherine Helmer^{53,54}, Charles N. Rotimi²⁶, Christian M. Shaffer⁵⁵, Christian Müller^{56,57}, Cinzia Sala⁵⁸, Cornelia M. van Duijn²², Aude Saint-Pierre^{1,59}, Daniel Ackermann⁴⁷, Daniel Shriner²⁶, Daniela Ruggiero¹⁰, Daniela Toniolo^{58,60}, Yingchang Lu⁶¹, Daniele Cusi⁶², Darina Czamara⁶³, David Ellinghaus³⁸, David S. Siscovick⁶⁴, Douglas Ruderfer⁶⁵, Christian Gieger⁶⁶, Harald Grallert^{67,68,69}, Elena Rohtchina⁷⁰, Elizabeth J. Atkinson⁷¹, Elizabeth G. Holliday^{72,73}, Eric Boerwinkle³⁴, Erika Salvi⁶², Erwin P. Bottinger⁶¹, Federico Murgia⁷⁴, Fernando Rivadeneira³⁹, Florian Ernst², Florian Kronenberg⁴⁵, Frank B. Hu⁷⁵, Gerjan J. Navis⁷⁶, Gary C. Curhan⁷⁷, George B. Ehret⁷⁸, Georg Homuth², Stefan Coassin⁴⁵, Gian-Andri Thun^{79,80}, Giorgio Pistis⁵⁸,

Giovanni Gambaro⁸¹, Giovanni Malerba⁸, Grant W. Montgomery⁸², Gudny Eiriksdottir³⁵, Gunnar Jacobs⁸³, Guo Li⁶⁴, H-Erich Wichmann^{84,85,86}, Harry Campbell⁸⁷, Helena Schmidt⁸⁸, Henri Wallaschofski^{89,90}, Henry Völzke^{3,90}, Hermann Brenner^{27,28}, Heyo K. Kroemer⁹¹, Holly Kramer¹⁹, Honghuang Lin⁹², I. Mateo Leach⁹³, Ian Ford⁹⁴, Idris Guessous^{95,96,97}, Igor Rudan⁸⁷, Inga Prokopenko⁹⁸, Ingrid Borecki²¹, Iris M. Heid^{4,66}, Ivana Kolcic⁹⁹, Ivana Persico⁷⁴, J. Wouter Jukema^{100,101,102,103}, James F. Wilson⁸⁷, Janine F. Felix²⁴, Jasmin Divers¹⁰⁴, Jean-Charles Lambert¹⁰⁵, Jeanette M. Stafford¹⁰⁴, Jean-Michel Gaspoz⁹⁵, Jennifer A. Smith¹⁰⁶, Jessica D. Faul¹⁰⁷, Jie Jin Wang¹⁰⁸, Jingzhong Ding¹⁰⁹, Joel N. Hirschhorn^{15,16,110}, John Attia^{71,72}, John B. Whitfield⁸², John Chalmers¹¹¹, Jorma Viikari¹¹², Josef Coresh^{7,113}, Joshua C. Denny¹¹⁴, Juha Karjalainen¹¹⁵, Jyotika K. Fernandes¹¹⁶, Karlhans Endlich¹¹⁷, Katja Butterbach²⁷, Keith L. Keene¹¹⁸, Kurt Lohman⁴⁶, Laura Portas⁷⁴, Lenore J. Launer¹¹⁹, Leo-Pekka Lyytikäinen¹²⁰, Loic Yengo^{121,122,123}, Lude Franke¹¹⁵, Luigi Ferrucci¹²⁴, Lynda M. Rose⁶, Lyudmyla Kedenko⁴⁹, Madhumathi Rao¹², Maksim Struchalin^{125,126}, Marcus E. Kleber¹²⁷, Margherita Cavalieri¹²⁸, Margot Haun⁴⁵, Marilyn C. Cornelis⁷⁵, Marina Ciullo¹⁰, Mario Pirastu⁷⁴, Mariza de Andrade⁷¹, Mark A. McEvoy¹²⁹, Mark Woodward^{7,111,112,130}, Martin Adam^{79,80}, Massimiliano Cocca⁵⁸, Matthias Nauck^{89,90}, Medea Imboden^{79,80}, Melanie Waldenberger⁶⁷, Menno Pruijm¹³¹, Marie Metzger¹³², Michael Stumvoll⁴², Michele K. Evans¹³³, Michele M. Sale¹³⁴, Mika Kähönen¹³⁵, Mladen Boban⁹⁹, Murielle Bochud¹³⁶, Myriam Rheinberger⁵, Niek Verweij⁹³, Nabila Bouatia-Naji^{137,138}, Nicholas G. Martin^{82,139}, Nick Hastie³¹, Nicole Probst-Hensch^{79,80}, Nicole Soranzo¹⁴⁰, Olivier Devuyst¹⁴¹, Olli Raitakari¹⁴², Omri Gottesman⁶¹, Oscar H. Franco²⁴, Ozren Polasek⁹⁹, Paolo Gasparini²⁵, Patricia B. Munroe^{143,144}, Paul M. Ridker¹⁴⁵, Paul Mitchell¹⁰⁸, Paul Muntner^{146,147}, Christa Meisinger⁶⁸, Johannes H. Smit¹⁴⁸, ICBP Consortium[†], AGEN Consortium[†], CARDIOGRAM[†], CHARGE-Heart Failure Group[†], ECHOGen Consortium[†], Peter Kovacs¹⁴⁹, Philipp S. Wild¹⁵⁰, Philippe Froguel^{121,122,123}, Rainer Rettig¹⁵¹, Reedik Mägi⁴⁰, Reiner Biffar¹⁵², Reinhold Schmidt¹²⁸, Rita P.S. Middelberg⁸², Robert J. Carroll¹¹⁴, Brenda W. Penninx¹⁴⁸, Rodney J. Scott¹⁵³, Ronit Katz¹⁵⁴, Sanaz Sedaghat²⁴, Sarah H. Wild⁸⁷, Sharon L.R. Kardia¹⁰⁶, Sheila Ulivi¹⁵⁵, Shih-Jen Hwang¹⁷, Stefan Enroth⁴⁴, Stefan Kloiber⁶³, Stella Trompet¹⁰⁰, Benedicte Stengel¹³², Stephen J. Hancock^{72,73}, Stephen T. Turner¹⁵⁶, Sylvia E. Rosas¹⁸, Sylvia Stracke^{105,157}, Tamara B. Harris¹¹⁹, Tanja Zeller^{56,57}, Tatijana Zemunik⁹⁹, Terho Lehtimäki¹²⁰, Thomas Illig⁶⁸, Thor Aspelund^{35,36}, Tiit Nikopensius^{40,41}, Tonu Esko^{15,40,41}, Toshiko Tanaka¹²⁴, Ulf Gyllensten⁴⁴, Uwe Völker^{2,90}, Valur Emilsson^{35,158}, Veronique Vitart³¹, Ville Aalto¹⁵⁹, Vilmundur Gudnason^{35,36}, Vincent Chouraki¹⁰⁵, Wei-Min Chen¹³⁴, Wilmar Igl⁴⁴, Winfried März¹⁶⁰, Wolfgang Koenig¹⁶¹, Wolfgang Lieb⁸³, Ruth J.F. Loos^{61,162}, Yongmei Liu⁴⁶, Harold Snieder³⁰, Peter P. Pramstaller^{1,163,164}, Afshin Parsa¹⁶⁵, Jeffrey R. O'Connell³², Katalin Susztak¹⁸, Pavel Hamet¹⁶⁶, Johanne Tremblay¹⁶⁶, Ian H. de Boer¹⁵⁴, Carsten A. Böger^{5,**}, Wolfram Goessling^{9,**}, Daniel I. Chasman^{6,145,**}, Anna Köttgen^{7,11,**}, W.H. Linda Kao^{7,113,**,‡} & Caroline S. Fox^{17,167,**}

¹ Center for Biomedicine, European Academy of Bozen/Bolzano (EURAC), affiliated to the University of Lübeck, Via Galvani 31, Bolzano 39100, Italy.

² Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, Friedrich-Loeffler-Straße 15a, Greifswald 17487, Germany. ³ Institute for Community Medicine, University of Greifswald, Walther-Rathenau-Strasse 48, Greifswald 17487, Germany. ⁴ Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg 93053, Germany.

⁵ Department of Nephrology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg 93053, Germany. ⁶ Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, Massachusetts 02215, USA. ⁷ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, Maryland 21205, USA. ⁸ Department of Life and Reproduction Sciences, University of Verona, Strada Le Grazie 8, Verona 37134, Italy. ⁹ Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, New Research Building 77 Avenue Louis Pasteur, Room 458, Boston, Massachusetts 02115, USA. ¹⁰ Institute of Genetics and Biophysics "Adriano Buzzati-Traverso"—CNR, Via P. Castellino 111, Napoli 80131, Italy. ¹¹ Department of Internal Medicine IV, University Hospital Freiburg, Berliner Allee 29, Freiburg 79110, Germany.

¹² Division of Nephrology/Tufts Evidence Practice Center, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA.

¹³ Department of Biostatistics, Boston University School of Public Health, 715 Albany Street, Boston, Massachusetts 02118, USA. ¹⁴ Department of Neurology, Boston University School of Medicine, 72 East Concord ST B603, Boston, Massachusetts 02118, USA. ¹⁵ Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. ¹⁶ Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 2142, USA. ¹⁷ NHLBI's Framingham Heart Study and the Center for Population

Studies, 73 Mt Wayte Avenue, Suite 2, Framingham, Massachusetts 01702, USA. ¹⁸ Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, 415 Curie Boulevard, 405B Clinical Research Building, Philadelphia, Pennsylvania 19104-4539, USA. ¹⁹ Department of Public Health Sciences, Loyola Medical Center, 2160 S First Avenue, Maywood, Illinois 60153, USA. ²⁰ Laboratory of Neurogenetics, Building 35—Porter Building, 1A1015, National Institute on Aging/NIH, Bethesda, Maryland 20892, USA. ²¹ Division of Statistical Genomics, Washington University School of Medicine, 4444 Forest Park Boulevard, Box 8506, St Louis, Missouri 63108, USA. ²² Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Dr Molewaterplein 50, PO Box 2040, Rotterdam 3000 CA, The Netherlands. ²³ Centre for Medical Systems Biology Leiden, Dr Molewaterplein 50, PO Box 2040, Rotterdam 3000 CA, The Netherlands. ²⁴ Department of Epidemiology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands. ²⁵ Institute for Maternal and Child Health—IRCCS “Burlo Garofolo” and University of Trieste, via dell’Istria 65/1, Trieste 34137, Italy. ²⁶ Center for Research on Genomics and Global Health, National Human Genome Research Institute, Building 12A, Room 4047, 12 South Dr, MSC 5635, Bethesda, Maryland 20892-5635, USA. ²⁷ Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg 69120, Germany. ²⁸ German Cancer Consortium (DKTK), Im Neuenheimer Feld 581, Heidelberg 69120, Germany. ²⁹ Laboratory of Personality and Cognition, National Institute on Aging, National Institutes of Health, NIH Biomedical Center, 251 Bayview Boulevard, Suite 100, Baltimore, Maryland 21224, USA. ³⁰ Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Center Groningen, PO Box 30001, Groningen 9700 RB, The Netherlands. ³¹ MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK. ³² Department of Medicine, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, Maryland 21201, USA. ³³ Geriatric Research and Education Clinical Center, Veterans Administration Medical Center, 10 North Greene Street, Baltimore, Maryland 21201, USA. ³⁴ Human Genetics Center, University of Texas Health Science Center at Houston, 1200 Pressler St Suite 453E, Houston, Texas 77030, USA. ³⁵ Icelandic Heart Association, Research Institute, Holtasmari 1, Kopavogur 201, Iceland. ³⁶ University of Iceland, Sæmundargötu 2, Reykjavik 101, Iceland. ³⁷ Division of Nephrology, University of Mississippi, 2500 North State Street, Jackson, Mississippi 39216, USA. ³⁸ Institute of Clinical Molecular Biology, Christian-Albrechts University of Kiel, Schittenhelmstraße 12, Kiel 24105, Germany. ³⁹ Department of Internal Medicine, Erasmus University Medical Center, PO Box 1738, Rotterdam 3000 DR, The Netherlands. ⁴⁰ Estonian Genome Center of University of Tartu (EGCUT), Riia 23B, Tartu 51010, Estonia. ⁴¹ Institute of Molecular and Cell Biology, University of Tartu and Estonian Biocenter, Riia 23, Tartu 51010, Estonia. ⁴² Department of Medicine, University of Leipzig, Liebigstraße 18, Leipzig 04103, Germany. ⁴³ Division of Nephrology, Department of Medicine, University of Verona, Piazzale Aristide Stefani 1, Verona 37126, Italy. ⁴⁴ Uppsala University, Department of Immunology, Genetics and Pathology, Biomedical Center, SciLifeLab, Uppsala University, Uppsala SE- 75108, Sweden. ⁴⁵ Innsbruck Medical University, Division of Genetic Epidemiology, Schoepfstraße 41, Innsbruck 6020, Austria. ⁴⁶ Internal Medicine Department, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1053, USA. ⁴⁷ Nephrology Division, Department of Specialties of Internal Medicine, Geneva University Hospital, 4 rue Gabrielle-Perret-Gentil, Geneve 1211, Switzerland. ⁴⁸ Department of Clinical Genetics, Erasmus University Medical Center, Dr Molewaterplein 50, PO Box 2040, Rotterdam 3000 CA, The Netherlands. ⁴⁹ First Department of Internal Medicine, Paracelsus Medical University/Salzbürger Landeskliniken, Müllner Hauptstraße 48, Salzburg 5020, Austria. ⁵⁰ University Medical Centre Mannheim, 5th Department of Medicine, University of Heidelberg, Theodor Kutzer Ufer 1-3, Mannheim 68167, Germany. ⁵¹ Department of Pharmacology and Therapeutics, University College Cork, Clinical Investigations Building, Western Rd, Cork, Ireland. ⁵² Division of Nephrology, University of California, San Francisco Medical School and San Francisco VA Medical Center, 4150 Clement Street, San Francisco, California 94121, USA. ⁵³ INSERM, ISPED, Centre INSERM U897—Epidemiologie-Biostatistique, Bordeaux F-33000, France. ⁵⁴ Université Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux F-33000, France. ⁵⁵ Vanderbilt University School of Medicine, 2215-B Garland Avenue 1224—MRB4 (Light Hall) Nashville, Tennessee 37232, USA. ⁵⁶ University Heart Center Hamburg, Clinic for general and interventional cardiology, Martinistraße 52, Hamburg 20246, Germany. ⁵⁷ German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Lübeck/Kiel, Martinistraße 52, Hamburg 20246, Germany. ⁵⁸ Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Via Olgettina 58, Milano 20132, Italy. ⁵⁹ INSERM U1078, Etablissement Français du Sang, 46 rue Félix Le Dantec, CS 51819, Brest Cedex 2 29218, France. ⁶⁰ Institute of Molecular Genetics-CNR, Via Abbiategrosso 207, Pavia 27100, Italy. ⁶¹ The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA. ⁶² Department of Health Sciences, University of Milano, Via Antonio di Rudini 8, Milano 20142, Italy. ⁶³ Max Planck Institute of Psychiatry, Kraepelinstraße 2-10, Munich 80804, Germany. ⁶⁴ Cardiovascular Health Research Unit, Departments of Epidemiology and Medicine, University of Washington, 1730 Minor Ave, Suite 1360, Seattle, Washington 98101, USA. ⁶⁵ Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA. ⁶⁶ Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. ⁶⁷ Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. ⁶⁸ Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany. ⁶⁹ German Center for Diabetes Research (DZD), Ingolstädter Landstraße 1, Neuherberg 85764, Germany. ⁷⁰ Westmead Millennium Institute, Centre for Vision Research, University of Sydney, C24 Westmead Hospital, New South Wales 2145, Australia. ⁷¹ Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. ⁷² Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, HMRI Building1, Kookaburra Circuit, New Lambton New South Wales 2305, Australia. ⁷³ Clinical Research Design, Information Technology and Statistical Support, Hunter Medical Research Institute, Newcastle, 1 Kookaburra Circuit, New Lambton Heights, New South Wales 2305, Australia. ⁷⁴ Institute of Population Genetics—CNR, Traversa La Crucca 3, 07040 Reg. Balduca, Li Punti, Sassari, Italy. ⁷⁵ Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Building 2, Boston, Massachusetts 02115, USA. ⁷⁶ Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen 9713 GZ, The Netherlands. ⁷⁷ Brigham and Women’s Hospital and Channing Laboratory, Harvard Medical School, 181 Longwood Avenue, Boston, Massachusetts 02115, USA. ⁷⁸ Cardiology, Department of Specialties of Internal Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland. ⁷⁹ Swiss Tropical and Public Health Institute, PO Box 4002, Basel, Switzerland. ⁸⁰ University of Basel, Petersplatz 1, Basel 4003, Switzerland. ⁸¹ Division of Nephrology, Department of Internal Medicine and Medical Specialties, Columbus-Gemelli University Hospital, Catholic University, Via Moscatti 31, Rome 00168, Italy. ⁸² Genetic Epidemiology, Queensland Institute of Medical Research, QIMR, PO Royal Brisbane Hospital, Queensland 4029, Australia. ⁸³ Institute of Epidemiology and Biobank popgen, Christian-Albrechts University, Niemannsweg 11, Kiel 24105, Germany. ⁸⁴ Institute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, Neuherberg 85764, Germany. ⁸⁵ Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany. ⁸⁶ Klinikum Grosshadern, Ingolstädter Landstraße 1, Neuherberg 85764, Germany. ⁸⁷ Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG Scotland, UK. ⁸⁸ Austrian Stroke Prevention Study, Institute of Molecular Biology and Biochemistry, Department of Neurology, Medical University Graz, Harrachgasse 21, Graz 8010, Austria. ⁸⁹ Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald 17475, Germany. ⁹⁰ German Center for Cardiovascular Research (DZHK), Partner site Greifswald, Ferdinand-Sauerbruch-Straße, Greifswald 17475, Germany. ⁹¹ Institute of Pharmacology, University of Greifswald, Friedrich-Loeffler-Straße 23d, Greifswald 17487, Germany. ⁹² Boston University School of Medicine, 72 East Concord Street, B-616, Boston, Massachusetts 02118, USA. ⁹³ Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands. ⁹⁴ Robertson Centre for Biostatistics, University of Glasgow, R1122B Level 11, Robertson Centre, Boyd Orr Building, Glasgow G12 8QQ, UK. ⁹⁵ Division of Primary Care Medicine, Department of Community

Medicine, Primary Care and Emergency Medicine, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland. ⁹⁶Community Prevention Unit, University Institute of Social and Preventive Medicine, Lausanne University Hospital, Route de la Corniche 10, Lausanne 1010, Switzerland. ⁹⁷Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, Georgia 30322, USA. ⁹⁸Department of Genomics of Common Disease, School of Public Health, Imperial College London, London W12 0NN, UK. ⁹⁹Croatian Centre for Global Health, University of Split Medical School, Šoltanska 2, Split 21000, Croatia. ¹⁰⁰Department of Cardiology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The Netherlands. ¹⁰¹Interuniversity Cardiology Institute of the Netherlands (ICIN), Moreelsepark 1, Utrecht 3511 EP, The Netherlands. ¹⁰²Eindhoven Laboratory for Experimental Vascular Medicine, Albinusdreef 2, Leiden 2333 ZA, The Netherlands. ¹⁰³Durrer Center for Cardiogenetic Research, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. ¹⁰⁴Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest University Health Sciences, 2326 Medical Center Boulevard, Winston-Salem, North Carolina 27157-1063, USA. ¹⁰⁵INSERM U744, Institut Pasteur de Lille, 1 rue du Pr. Calmette, Lille Cédex 59019, France. ¹⁰⁶Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, Michigan 48109-2029, USA. ¹⁰⁷Survey Research Center, Institute for Social Research, University of Michigan, 426 Thompson Street, #3456, Ann Arbor, Michigan 48104, USA. ¹⁰⁸Centre for Vision Research, Westmead Millennium Institute, University of Sydney, C24 Westmead Hospital, New South Wales 2145, Australia. ¹⁰⁹Wake Forest School of Medicine, Department of Internal Medicine/Geriatrics, Medical center Boulevard, Winston-Salem, North Carolina 27157, USA. ¹¹⁰Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 0330, Boston, Massachusetts 02115, USA. ¹¹¹University of Sydney, The George Institute for Global Health, Level 10, King George V Building, 83-117 Missenden Road, Camperdown, New South Wales 2050, Australia. ¹¹²Department of Medicine, University of Turku, Turku University Hospital, PO Box 52, Turku 20521, Finland. ¹¹³Welch Center for Prevention, Epidemiology and Clinical Research, 2024 East Monument St, Suite 2-600, Baltimore, Maryland 21287, USA. ¹¹⁴Vanderbilt University School of Medicine, 448 Eskind Biomedical Library, 2209 Garland Avenue, Nashville, Tennessee 37212, USA. ¹¹⁵Department of Genetics, University of Groningen, University Medical Centre Groningen, PO Box 72, Groningen 9700 AB, The Netherlands. ¹¹⁶Division of Endocrinology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, South Carolina 29425, USA. ¹¹⁷Institute of Anatomy and Cell Biology, University of Greifswald, Friedrich-Loeffler-Straße 23c, Greifswald 17487, Germany. ¹¹⁸Center for Health Disparities, Department of Biology, East Carolina University, 1001 East 10th Street, N209 Howell Science Complex Mailstop 551, Greenville, North Carolina 27858, USA. ¹¹⁹Intramural Research Program, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Gateway Building, 3C309, 7201 Winsconsin Avenue, Bethesda, Maryland 20892-9205, USA. ¹²⁰Department of Clinical Chemistry, Fimlab Laboratories, University of Tampere, School of Medicine, Tampere 33520, Finland. ¹²¹CNRS UMR 8199, 1 Rue du Professeur Calmette, Lille 59000, France. ¹²²Lille Pasteur Institute, 1 Rue du Professeur Calmette, Lille 59000, France. ¹²³Lille II University, 42 Rue Paul Duez, Lille 59000, France. ¹²⁴Clinical Research Branch, National Institute on Aging, 251 Bayview Blvd, Baltimore, Maryland 21250, USA. ¹²⁵Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Dr Molewaterplein, Rotterdam 50-603015 GE, The Netherlands. ¹²⁶Department of Forensic Molecular Biology, Erasmus University Medical Center, Dr Molewaterplein, Rotterdam 50-603015 GE, The Netherlands. ¹²⁷Medical Clinic V, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany. ¹²⁸Austrian Stroke Prevention Study, Department of Neurology, Division of Special Neurology, Medical University Graz, Auenbruggerplatz 22, Graz 8036, Austria. ¹²⁹Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1, HRMC, New South Wales 2310, Australia. ¹³⁰The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK. ¹³¹Service of Nephrology, Lausanne University Hospital, Rue du Bugnon 17, Lausanne 1005, Switzerland. ¹³²Inserm UMRS 1018, CESP Team 10, Université Paris-Sud, 16 avenue Paul Vaillant Couturier, Villejuif 94807, France. ¹³³Health Disparities Research Section, Clinical Research Branch, National Institute on Aging, National Institutes of Health, NIH Biomedical Center, 251 Bayview Boulevard, Suite 100, Baltimore, Maryland 21224, USA. ¹³⁴Center for Public Health Genomics, Department of Medicine (Cardiovascular Medicine), University of Virginia, PO Box 800717, Charlottesville, Virginia 22908, USA. ¹³⁵Department of Clinical Physiology, Tampere University Hospital, University of Tampere, School of Medicine, Tampere 33521, Finland. ¹³⁶University Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Route de la Corniche 2, Epalinges CH-1066, Switzerland. ¹³⁷INSERM UMR970, Paris Cardiovascular Research Center (PARCC), 56 rue Leblanc, Paris F-75015, France. ¹³⁸Paris Descartes University, Faculty of medicine, Paris Cité Sorbonne, 12 Rue de l'école de Médecine, Paris F-75006, France. ¹³⁹Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. ¹⁴⁰Wellcome Trust Sanger Institute, Hinxton CB10 1HH, UK. ¹⁴¹University of Zurich, Institute of Physiology, Mechanisms of Inherited Kidney Disorders Group, Winterthurerstrasse 190, Zürich 8057, Switzerland. ¹⁴²Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku University Hospital, Department of Clinical Physiology, PO Box 52, Turku 20521, Finland. ¹⁴³Department Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK. ¹⁴⁴NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary University of London, London EC1M 6BQ, UK. ¹⁴⁵Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts 02115, USA. ¹⁴⁶University of Alabama at Birmingham, Department of Medicine, 1530 3rd Avenue, South Birmingham, Alabama 35294-0022, USA. ¹⁴⁷University of Alabama at Birmingham, Department of Epidemiology, 1530 3rd Avenue, South Birmingham, Alabama 35294-0022, USA. ¹⁴⁸Department of Psychiatry and EMGO + Institute, VU University Medical Center, A.J. Ernststraat 1187, Amsterdam 1081 HL, The Netherlands. ¹⁴⁹IFB AdiposityDiseases, University of Leipzig, Liebigstraße 21, Leipzig 04103, Germany. ¹⁵⁰Medical University Center Mainz, Langenbeckstraße 1, Mainz 55131, Germany. ¹⁵¹Institute of Physiology, University of Greifswald, Greifswald 17487, Germany. ¹⁵²Clinic for Prosthodontic Dentistry, Gerostomatology and Material Science, University of Greifswald, Rotgerberstraße 8, Greifswald 17475, Germany. ¹⁵³School of Biomedical Sciences and Pharmacy, University of Newcastle, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1, HRMC, New South Wales 2310, Australia. ¹⁵⁴Kidney Research Institute, University of Washington, Box 359606, 325 9th Avenue, Seattle, Washington 98104, USA. ¹⁵⁵Institute for Maternal and Child Health—IRCCS "Burlo Garofolo", Via dell'Istria 65, Trieste 34137, Italy. ¹⁵⁶Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. ¹⁵⁷Clinic for Internal Medicine A, University of Greifswald, Friedrich-Loeffler-Straße 23a, Greifswald 17475, Germany. ¹⁵⁸Faculty of Pharmaceutical Sciences, University of Iceland, Sæmundargata 2, Reykjavik 101, Iceland. ¹⁵⁹Department of Clinical Physiology, Turku University Hospital, Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, PO Box 52, Turku 20521, Finland. ¹⁶⁰Synlab Academy, Synlab Services GmbH, Oberer Eselsberg 45, Ulm 89081, Germany. ¹⁶¹Department of Internal Medicine II—Cardiology, University of Ulm Medical Centre, Albert-Einstein-Allee 23, Ulm 89081, Germany. ¹⁶²The Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York, New York 10029, USA. ¹⁶³Department of Neurology, General Central Hospital, Via Lorenz Bohler 5, Bolzano 39100, Italy. ¹⁶⁴Department of Neurology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23538, Germany. ¹⁶⁵University of Maryland Medical School, Division of Nephrology, 685 W. Baltimore Street, MSTF 314, Baltimore, Maryland 21201, USA. ¹⁶⁶CRCHUM, University of Montreal, CHUM Research Center, Technopôle Angus, 900 Saint-Denis, Montreal, Québec, Canada H2X 0A9. ¹⁶⁷Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115, USA. * These authors contributed equally to this work. ** These authors jointly supervised this work. †A full list of consortium members appears at the end of the paper.

‡Deceased.

ICBP Consortium

Goncalo R. Abecasis¹⁶⁸, Linda S. Adair¹⁶⁹, Myriam Alexander¹⁷⁰, David Altshuler^{171,172}, Najaf Amin²⁴, Dan E. Arking¹⁷³, Pankaj Arora¹⁷⁴, Yurii Aulchenko²⁴, Stephan J.L. Bakker⁷⁶, Stefania Bandinelli¹⁷⁵, Ines Barroso¹⁴⁰, Jacques S. Beckmann¹⁷⁶, John P. Beilby¹⁷⁷, Richard N. Bergman¹⁷⁸, Sven Bergmann¹⁷⁶, Joshua C. Bis¹⁷⁹, Michael Boehnke¹⁶⁸, Lori L. Bonnycastle¹⁸⁰, Stefan R. Bornstein¹⁸¹, Michiel L. Bots¹⁸², Jennifer L. Bragg-Gresham¹⁶⁸, Stefan-Martin Brand¹⁸³, Eva Brand¹⁸⁴, Peter S. Braund¹⁸⁵, Morris J. Brown¹⁸⁶, Paul R. Burton¹⁸⁷, Juan P. Casas¹⁸⁸, Mark J. Caulfield¹⁸⁹, Aravinda Chakravarti¹⁷³, John C. Chambers¹⁹⁰, Giriraj R. Chandak¹⁹¹, Yen-Pei C. Chang¹⁹², Fadi J. Charchar¹⁹³, Nish Chaturvedi¹⁹⁴, Yoon Shin Cho¹⁹⁵, Robert Clarke¹⁹⁶, Francis S. Collins¹⁸⁰, Rory Collins¹⁹⁶, John M. Connell¹⁹⁷, Jackie A. Cooper¹⁹⁸, Matthew N. Cooper¹⁹⁹, Richard S. Cooper²⁰⁰, Anna Maria Corsi²⁰¹, Marcus Dörr²⁰², Santosh Dahgam²⁰³, John Danesh¹⁷⁰, George Davey Smith²⁰⁴, Ian N.M. Day²⁰⁴, Panos Deloukas¹⁴⁰, Matthew Denniff¹⁸⁵, Anna F. Dominiczak²⁰⁵, Yanbin Dong²⁰⁶, Ayo Doumatey²⁶, Paul Elliott¹⁹⁰, Roberto Elosua²⁰⁷, Jeanette Erdmann²⁰⁸, Susana Eyheramendy²⁰⁹, Martin Farrall²¹⁰, Cristiano Fava²¹¹, Terrence Forrester²¹², F. Gerald R. Fowkes⁸⁷, Ervin R. Fox²¹³, Timothy M. Frayling²¹⁴, Pilar Galan²¹⁵, Santhi K. Ganesh²¹⁶, Melissa Garcia²¹⁷, Tom R. Gaunt²⁰⁴, Nicole L. Glazer¹⁷⁹, Min Jin Go¹⁹⁵, Anuj Goel²¹⁰, Jürgen Grässler¹⁸¹, Diederick E. Grobbee¹⁸², Leif Groop²¹⁸, Simonetta Guarrera²¹⁹, Xiuqing Guo²²⁰, David Hadley²²¹, Anders Hamsten²²², Bok-Ghee Han¹⁹⁵, Rebecca Hardy²²³, Anna-Liisa Hartikainen²²⁴, Simon Heath²²⁵, Susan R. Heckbert²²⁶, Bo Hedblad²¹¹, Serge Hercberg²¹⁵, Dena Hernandez²⁰, Andrew A. Hicks¹, Gina Hilton¹⁷³, Aroon D. Hingorani²²⁷, Judith A. Hoffman Bolton⁷, Jemma C. Hopewell¹⁹⁶, Philip Howard²²⁸, Steve E. Humphries¹⁹⁸, Steven C. Hunt²²⁹, Kristian Hveem²³⁰, M. Arfan Ikram²⁴, Muhammad Islam^{231,232}, Naoharu Iwai^{233,234}, Marjo-Riitta Jarvelin¹⁹⁰, Anne U. Jackson¹⁶⁸, Tazeen H. Jafar^{231,232}, Charles S. Janipalli¹⁹¹, Toby Johnson¹⁸⁹, Sekar Kathiresan²³⁵, Kay-Tee Khaw¹⁷⁰, Hyung-Lae Kim¹⁹⁵, Sanjay Kinra²³⁶, Yoshikuni Kita²³⁷, Mika Kivimaki²²⁷, Jaspal S. Kooner²³⁸, M.J. Kranthi Kumar¹⁹¹, Diana Kuh²²³, Smita R. Kulkarni²³⁹, Meena Kumari²⁴⁰, Johanna Kuusisto²⁴¹, Tatiana Kuznetsova²⁴², Markku Laakso²⁴¹, Maris Laan²⁴³, Jaana Laitinen²⁴⁴, Edward G. Lakatta²⁴⁵, Carl D. Langefeld²⁴⁶, Martin G. Larson²⁴⁷, Mark Lathrop²²⁵, Debbie A. Lawlor²⁰⁴, Robert W. Lawrence¹⁹⁹, Jong-Young Lee¹⁹⁵, Nanette R. Lee²⁴⁸, Daniel Levy²⁴⁷, Yali Li²⁴⁹, Will T. Longstreth²⁵⁰, Jian'an Luan²⁵¹, Gavin Lucas²⁰⁷, Barbara Ludwig¹⁸¹, Massimo Mangino²⁵², K. Radha Mani¹⁹¹, Michael G. Marmot²²⁷, Francesco U.S. Mattace-Raso²⁴, Giuseppe Matullo²⁵³, Wendy L. McArdle²⁵⁴, Colin A. McKenzie²¹², Thomas Meitinger²⁵⁵, Olle Melander²¹¹, Pierre Meneton²⁵⁶, James F. Meschia²⁵⁷, Tetsuro Miki^{258,259}, Yuri Milaneschi¹²⁴, Karen L. Mohlke²⁶⁰, Vincent Mosser²⁶¹, Mario A. Morken¹⁸⁰, Richard W. Morris²⁶², Thomas H. Mosley²⁶³, Samer Najjar²⁶⁴, Narisu Narisu¹⁸⁰, Christopher Newton-Cheh¹⁷⁴, Khanh-Dung Hoang Nguyen¹⁷³, Peter Nilsson²¹¹, Fredrik Nyberg²⁰³, Christopher J. O'Donnell²⁴⁷, Toshio Ogihara²⁶⁵, Takayoshi Ohkubo²⁶⁶, Tomonori Okamura^{233,234}, Rick Twee-Hee Ong²⁶⁷, Halit Ongen²¹⁰, N. Charlotte Onland-Moret¹⁸², Paul F. O'Reilly¹⁹⁰, Elin Org²⁴³, Marco Orru²⁶⁸, Walter Palmas²⁶⁹, Jutta Palmen¹⁹⁸, Lyle J. Palmer¹⁹⁹, Nicholette D. Palmer²⁴⁶, Alex N. Parker²⁷⁰, John F. Peden²¹⁰, Leena Peltonen¹⁴⁰, Markus Perola²⁷¹, Vasyl Pihur¹⁷³, Carl G.P. Platou²³⁰, Andrew Plump²⁷², Dorairajan Prabhakaran²⁷³, Bruce M. Psaty¹⁷⁹, Leslie J. Raffel²²⁰, Dabeeru C. Rao²⁷⁴, Asif Rasheed²⁷⁵, Fulvio Ricceri²⁵³, Kenneth M. Rice²⁷⁶, Annika Rosengren²⁷⁷, Jerome I. Rotter²²⁰, Megan E. Rudock²⁷⁸, Siim Söber²⁴³, Tunde Salako²⁷⁹, Danish Saleheen²⁷⁵, Veikko Salomaa²⁷¹, Nilesh J. Samani¹⁸⁵, Steven M. Schwartz²²⁶, Peter E.H. Schwarz²⁸⁰, Laura J. Scott¹⁶⁸, James Scott²³⁸, Angelo Scuteri²⁴⁵, Joban S. Sehmi²³⁸, Mark Seielstad²⁸¹, Sudha Seshadri¹⁴, Pankaj Sharma²⁸², Sue Shaw-Hawkins¹⁸⁹, Gang Shi²⁷⁴, Nick R.G. Shrine¹⁸⁷, Eric J.G. Sijbrands²⁴, Xueling Sim²⁸³, Andrew Singleton²⁰, Marketa Sjögren²¹¹,

Nicholas L. Smith²²⁶, Maria Soler Artigas¹⁸⁷, Tim D. Spector²⁵², Jan A. Staessen²⁴⁴, Alena Stancakova²⁴¹, Nanette I. Steinle¹⁹², David P. Strachan²²¹, Heather M. Stringham¹⁶⁸, Yan V. Sun¹⁰⁶, Amy J. Swift¹⁸⁰, Yasuharu Tabara^{258,259}, E-Shyong Tai²⁸⁴, Philippa J. Talmud¹⁹⁸, Andrew Taylor²⁴⁰, Janos Terzic²⁸⁵, Dag S. Thelle²⁸⁶, Martin D. Tobin¹⁸⁹, Maciej Tomaszewski¹⁸⁵, Vikal Tripathy²⁷³, Jaakko Tuomilehto²⁸⁷, Ioanna Tzoulaki¹⁹⁰, Manuela Uda²⁶⁸, Hirotugu Ueshima²⁸⁸, Cuno S.P.M. Uiterwaal¹⁸⁴, Satoshi Umemura²⁸⁹, Pim van der Harst⁹³, Yvonne T. van der Schouw¹⁸², Wiek H. van Gilst⁹³, Erkki Vartiainen²⁷¹, Ramachandran S. Vasan²⁴⁷, Gudrun Veldre²⁴³, Germaine C. Verwoert²⁴, Margus Viigimaa²⁹⁰, D.G. Vinay¹⁹¹, Paolo Vineis²⁹¹, Benjamin F. Voight²³⁵, Peter Vollenweider²⁹², Lynne E. Wagenknecht²⁴⁶, Louise V. Wain¹⁸⁷, Xiaoling Wang²⁰⁶, Thomas J. Wang²⁴⁷, Nicholas J. Wareham²⁵¹, Hugh Watkins²¹⁰, Alan B. Weder²¹⁶, Peter H. Whincup²²¹, Kerri L. Wiggins¹⁷⁹, Jacqueline C.M. Witteman²⁴, Andrew Wong²²³, Ying Wu²⁵⁹, Chittaranjan S. Yajnik²³⁹, Jie Yao²²⁰, J.H. Young²⁹³, Diana Zelenika²²⁵, Guangju Zhai²⁵², Weihua Zhang¹⁹⁰, Feng Zhang²⁵², Jing Hua Zhao²⁵¹, Haidong Zhu²⁰⁶, Xiaofeng Zhu²⁴⁹, Paavo Zitting²⁹⁴, Ewa Zukowska-Szzechowska²⁹⁵

¹⁶⁸Center for Statistical Genetics, Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, Michigan 48103, USA. ¹⁶⁹Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina 27599, USA. ¹⁷⁰Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK. ¹⁷¹Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. ¹⁷²Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA. ¹⁷³Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. ¹⁷⁴Center for Human Genetic Research, Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. ¹⁷⁵Geriatric Rehabilitation Unit, Azienda Sanitaria Firenze (ASF), 50125 Florence, Italy. ¹⁷⁶Département de Génétique Médicale, Université de Lausanne, Lausanne 1015, Switzerland. ¹⁷⁷Pathology and Laboratory Medicine, University of Western Australia, 6009 Crawley, Western Australia, Australia. ¹⁷⁸Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. ¹⁷⁹Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle 98195, Washington, USA. ¹⁸⁰National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. ¹⁸¹Department of Medicine III, Medical Faculty Carl Gustav Carus at the Technical University of Dresden, Dresden 01307, Germany. ¹⁸²Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3508 GA, The Netherlands. ¹⁸³Leibniz-Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Münster, Münster, Germany. ¹⁸⁴University Hospital Münster, Internal Medicine D, Münster, Germany. ¹⁸⁵Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK. ¹⁸⁶Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK. ¹⁸⁷Department of Health Sciences, University of Leicester, University Rd, Leicester LE1 7RH, UK. ¹⁸⁸Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. ¹⁸⁹Clinical Pharmacology and The Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. ¹⁹⁰Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK. ¹⁹¹Centre for Cellular and Molecular Biology (CCMB), Council of Scientific and Industrial Research (CSIR), Uppal Road, Hyderabad 500 007, India. ¹⁹²University of Maryland, School of Medicine, Baltimore, Maryland 21201, USA. ¹⁹³School of Science and Engineering, University of Ballarat, Ballarat 3353, Australia. ¹⁹⁴International Centre for Circulatory Health, National Heart & Lung Institute, Imperial College, London, UK. ¹⁹⁵Center for Genome Science, National Institute of Health, Seoul, Korea. ¹⁹⁶Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK. ¹⁹⁷University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK. ¹⁹⁸Centre for Cardiovascular Genetics, University College London, London WC1E 6JF, UK. ¹⁹⁹Centre for Genetic Epidemiology and Biostatistics, University of Western Australia, Crawley, Western Australia, Australia. ²⁰⁰Department of Preventive Medicine and Epidemiology, Loyola University Medical School, Maywood, Illinois, USA. ²⁰¹Tuscany Regional Health Agency, Florence, Italy. ²⁰²Department of Internal Medicine B, Ernst-Moritz-Arndt-University Greifswald, Greifswald 17487, Germany. ²⁰³Occupational and Environmental Medicine, Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden. ²⁰⁴MRC Centre for Causal Analyses in Translational Epidemiology, School of Social & Community Medicine, University of Bristol, Bristol BS8 2BN, UK. ²⁰⁵BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK. ²⁰⁶Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, 30912 Augusta, Georgia, USA. ²⁰⁷Cardiovascular Epidemiology and Genetics, Institut Municipal d'Investigació Mèdica, Barcelona Biomedical Research Park, 88 Doctor Aiguader, Barcelona 08003, Spain. ²⁰⁸Medizinische Klinik II, Universität zu Lübeck, 23562 Lübeck, Germany. ²⁰⁹Department of Statistics, Pontificia Universidad Católica de Chile, Vicuña Mackena, Santiago 4860, Chile. ²¹⁰Department of Cardiovascular Medicine, The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK. ²¹¹Department of Clinical Sciences, Lund University, SE-205 02 Malmö, Sweden. ²¹²Tropical Medicine Research Institute, University of the West Indies, Mona, Kingston, Jamaica. ²¹³Department of Medicine, University of Mississippi Medical Center, 2500 North State St, Jackson, Mississippi 39216, USA. ²¹⁴Genetics of Complex Traits, Peninsula Medical School, University of Exeter, EX1 2LU Exeter, UK. ²¹⁵U557 Institut National de la Santé et de la Recherche Médicale, U1125 Institut National de la Recherche Agronomique, Université Paris 13, F-93017 Bobigny, France. ²¹⁶Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor 48108, Michigan, USA. ²¹⁷Laboratory of Epidemiology, Demography, Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA. ²¹⁸Department of Clinical Sciences, Diabetes and Endocrinology Research Unit, University Hospital, SE-205 02 Malmö, Sweden. ²¹⁹Human Genetics Foundation (HUGEF), Via Lagrange 35, Torino 10123, Italy. ²²⁰Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, 90048 California, USA. ²²¹Division of Community Health Sciences, St George's University of London, London SW17 0RE, UK. ²²²Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, SE-171 77 Stockholm, Sweden. ²²³MRC Unit for Lifelong Health & Ageing, London WC1B 5JU, UK. ²²⁴Institute of Clinical Medicine/Obstetrics and Gynecology, University of Oulu, 90014 Oulu, Finland. ²²⁵Centre National de Génotypage, Commissariat de L'Energie Atomique, Institut de Génétique, 91000 Evry, France. ²²⁶Department of Epidemiology, University of Washington, Seattle, Washington 98195, USA. ²²⁷Epidemiology Public Health, UCL, London WC1E 6BT, UK. ²²⁸William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK. ²²⁹Cardiovascular Genetics, University of Utah, School of Medicine, Salt Lake City, 84132 Utah, USA. ²³⁰HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger 7600, Norway. ²³¹Department of Community

Health Sciences, Aga Khan University, 74800 Karachi, Pakistan. ²³²Department of Medicine, Aga Khan University, 74800 Karachi, Pakistan. ²³³Department of Genomic Medicine, National Cerebral and Cardiovascular Research Center, Suita 565-8565, Japan. ²³⁴Department of Preventive Cardiology, National Cerebral and Cardiovascular Research Center, Suita 565-8565, Japan. ²³⁵Medical Population Genetics, Broad Institute of Harvard and MIT, 5 Cambridge Center, Cambridge, Massachusetts 02142, USA. ²³⁶Division of Non-communicable disease Epidemiology, The London School of Hygiene and Tropical Medicine London, Keppel Street, London WC1E 7HT, UK. ²³⁷Department of Health Science, Shiga University of Medical Science, Otsu 520-2192, Japan. ²³⁸National Heart and Lung Institute, Imperial College London, London W12 0HS, UK. ²³⁹Diabetes Unit, KEM Hospital and Research Centre, Rasta Peth, Pune, 411011 Maharashtra, India. ²⁴⁰Genetic Epidemiology Group, Epidemiology and Public Health, UCL, London WC1E 6BT, UK. ²⁴¹Department of Medicine, University of Kuopio, Kuopio University Hospital, Kuopio 70210, Finland. ²⁴²Studies Coordinating Centre, Division of Hypertension and Cardiac Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Campus Sint Rafaël, Kapucijnenvoer 35, Block D, Box 7001, Leuven 3000, Belgium. ²⁴³Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia. ²⁴⁴Finnish Institute of Occupational Health, Finnish Institute of Occupational Health, Aapistie 1, Oulu 90220, Finland. ²⁴⁵Gerontology Research Center, National Institute on Aging, Baltimore, Maryland 21224, USA. ²⁴⁶Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157, USA. ²⁴⁷National Heart, Lung and Blood Institute Framingham Heart Study, Framingham, 01702-5827 Massachusetts, USA. ²⁴⁸Office of Population Studies Foundation, University of San Carlos, Talamban, Cebu 6000, Philippines. ²⁴⁹Department of Epidemiology and Biostatistics, Case Western Reserve University, 2103 Cornell Road, Cleveland, Ohio 44106, USA. ²⁵⁰Department of Medicine and Neurology, University of Washington, Seattle, Washington 98195, USA. ²⁵¹MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge CB2 0QQ, UK. ²⁵²Department of Twin Research and Genetic Epidemiology, King's College London, SE1 7EH London, UK. ²⁵³Department of Genetics, Biology and Biochemistry, University of Torino, Via Santena 19, Torino 10126, Italy. ²⁵⁴ALSPAC Laboratory, University of Bristol, Bristol BS8 2BN, UK. ²⁵⁵Institute of Human Genetics, Helmholtz Zentrum Munich, German Research Centre for Environmental Health, Neuherberg 85764, Germany. ²⁵⁶U872 Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, 75006 Paris, France. ²⁵⁷Mayo Clinic, Jacksonville, 32224 Florida, USA. ²⁵⁸Department of Basic Medical Research and Education, Ehime University Graduate School of Medicine, Toon 791-0295, Japan. ²⁵⁹Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Toon 791-0295, Japan. ²⁶⁰Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA. ²⁶¹Division of Genetics, GlaxoSmithKline, Philadelphia, Pennsylvania 19101, USA. ²⁶²Department of Primary Care and Population Health, UCL, London NW3 2PF, UK. ²⁶³Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, 39216 Mississippi, USA. ²⁶⁴Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, 21224-6825 Maryland, USA. ²⁶⁵Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. ²⁶⁶Tohoku University, Graduate School of Pharmaceutical Sciences and Medicine, Sendai 980-8578, Japan. ²⁶⁷Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore 138672, Singapore. ²⁶⁸Istituto di Neurogenetica e Neurofarmacologia, Consiglio Nazionale delle Ricerche, Cittadella Universitaria di Monserrato, 09042 Monserrato, Cagliari, Italy. ²⁶⁹Columbia University, New York, 10027 New York, USA. ²⁷⁰Amgen, 1 Kendall Square, Building 100, Cambridge, Massachusetts 02139, USA. ²⁷¹National Institute for Health and Welfare, Helsinki 00271, Finland. ²⁷²Merck Research Laboratory, 126 East Lincoln Avenue, Rahway, New Jersey 07065, USA. ²⁷³South Asia Network for Chronic Disease, Public Health Foundation of India, C-1/52, SDA, New Delhi 100016, India. ²⁷⁴Division of Biostatistics, Washington University School of Medicine, Saint Louis, Missouri 63110, USA. ²⁷⁵Center for Non-Communicable Diseases, 74800 Karachi, Pakistan. ²⁷⁶Department of Biostatistics, University of Washington, Seattle, 98105 Washington, USA. ²⁷⁷Department of Emergency and Cardiovascular Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 41685, Sweden. ²⁷⁸Epidemiology & Prevention, Division of Public Health Sciences, Wake Forest University, School of Medicine, Winston-Salem, North Carolina 27157, USA. ²⁷⁹University of Ibadan, PMB 5017 Ibadan, Nigeria. ²⁸⁰Prevention and Care of Diabetes, Department of Medicine III, Medical Faculty Carl Gustav Carus at the Technical University of Dresden, Dresden 01307, Germany. ²⁸¹Department of Laboratory Medicine, Institute of Human Genetics, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, California 94143, USA. ²⁸²Imperial College Cerebrovascular Unit (ICCRU), Imperial College, London W6 8RF, UK. ²⁸³Centre for Molecular Epidemiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. ²⁸⁴Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore. ²⁸⁵Faculty of Medicine, University of Split, 21000 Split, Croatia. ²⁸⁶Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo 0317, Norway. ²⁸⁷Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki 00271, Finland. ²⁸⁸Lifestyle-related Disease Prevention Center, Shiga University of Medical Science, Otsu 520-2192, Japan. ²⁸⁹Department of Medical Science and Cardiorespiratory Medicine, Yokohama City University School of Medicine, Yokohama 236-0004, Japan. ²⁹⁰Tallinn University of Technology, Institute of Biomedical Engineering, Ehitajate tee 5, Tallinn 19086, Estonia. ²⁹¹Department of Epidemiology and Public Health, Imperial College, Norfolk Place, London W2 1PG, UK. ²⁹²Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne 1011, Switzerland. ²⁹³Department of Medicine, Johns Hopkins University, Baltimore, 21205 Maryland, USA. ²⁹⁴Lapland Central Hospital, Department of Psychiatric, Box 8041, Rovaniemi 96101, Finland. ²⁹⁵Department of Internal Medicine, Diabetology, and Nephrology, Medical University of Silesia, Zabrze 41-800, Poland.

AGEN Consortium

Yukinori Okada^{296,297}, Jer-Yuarn Wu^{298,299}, Dongfeng Gu³⁰⁰, Fumihiko Takeuchi³⁰¹, Atsushi Takahashi²⁹⁶, Shiro Maeda³⁰², Tatsuhiro Tsunoda³⁰³, Peng Chen³⁰⁴, Su-Chi Lim^{305,306}, Tien-Yin Wong^{307,308,309}, Jianjun Liu²⁶⁷, Terri L. Young³¹⁰, Tin Aung^{307,308}, Yik-Ying Teo^{267,283,306,311,312}, Young Jin Kim³¹³, Daehee Kang³¹⁴, Chien-Hsiun Chen^{298,299}, Fuu-Jen Tsai²⁹⁹, Li-Ching Chang²⁹⁸, S.-J. Cathy Fann²⁹⁸, Hao Mei³¹⁵, James E. Hixson³⁴, Shufeng Chen³⁰⁰, Tomohiro Katsuya^{316,317}, Masato Isono³⁰¹, Eva Albrecht⁶⁶, Kazuhiko Yamamoto³¹⁸, Michiaki Kubo³¹⁹, Yusuke Nakamura³²⁰, Naoyuki Kamatani³²¹, Norihiro Kato³⁰¹, Jiang He³¹⁵, Yuan-Tsong Chen²⁹⁸, Toshihiro Tanaka^{297,322}

²⁹⁶Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. ²⁹⁷Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan. ²⁹⁸Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan. ²⁹⁹School of Chinese Medicine, China Medical University, Taichung 404, Taiwan. ³⁰⁰Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China. ³⁰¹Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. ³⁰²Laboratory for Endocrinology and Metabolism, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. ³⁰³Laboratory for Medical Informatics, RIKEN

Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. ³⁰⁴Saw Swee Hock School of Public Health, National University of Singapore, Singapore 119077, Singapore. ³⁰⁵Department of Medicine, Khoo Teck Puat Hospital, Singapore 768828, Singapore. ³⁰⁶Department of Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. ³⁰⁷Singapore Eye Research Institute, Singapore National Eye Centre, Singapore 168751, Singapore. ³⁰⁸Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. ³⁰⁹Centre for Eye Research Australia, University of Melbourne, East Melbourne, 3002 Victoria, Australia. ³¹⁰Center for Human Genetics, Duke University Medical Center, Durham, 27710 North Carolina, USA. ³¹¹Department of Statistics and Applied Probability, National University of Singapore, Singapore 117546, Singapore. ³¹²NUS Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore 119077, Singapore. ³¹³Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, 187 Chungcheongbuk-do, Korea. ³¹⁴Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 08826, Korea. ³¹⁵Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, 70112 Louisiana, USA. ³¹⁶Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. ³¹⁷Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. ³¹⁸Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan. ³¹⁹Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. ³²⁰Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. ³²¹Laboratory for International Alliance, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan. ³²²Laboratory for Cardiovascular Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan.

CARDIOGRAM

Muredach P. Reilly³²³, Heribert Schunkert^{57,324,325}, Themistocles L. Assimes³²⁶, Alistair Hall³²⁷, Christian Hengstenberg³²⁸, Inke R. König³²⁹, Reijo Laaksonen³³⁰, Ruth McPherson³³¹, John R. Thompson¹⁸⁷, Unnur Thorsteinsdottir^{332,333}, Andreas Ziegler³²⁹, Devin Absher³³⁴, Li Chen³³⁵, L. Adrienne Cupples^{13,247}, Eran Halperin^{336,337}, Mingyao Li³³⁸, Kiran Musunuru^{140,339,340}, Michael Preuss^{324,329}, Arne Schillert³²⁹, Gudmar Thorleifsson³³², George A. Wells³³⁵, Hilma Holm³³², Robert Roberts³³¹, Alexandre F.R. Stewart³³¹, Stephen Fortmann³²⁶, Alan Go³⁴¹, Mark Hlatky³²⁶, Carlos Iribarren³⁴¹, Joshua Knowles³²⁶, Richard Myers³³⁴, Thomas Quertermous³²⁶, Steven Sidney³⁴¹, Neil Risch³⁴², Hua Tang³⁴³, Stefan Blankenberg³⁴⁴, Renate Schnabel³⁴⁴, Christoph Sinning³⁴⁴, Karl J. Lackner³⁴⁵, Laurence Tiret³⁴⁶, Viviane Nicaud³⁴⁶, Francois Cambien³⁴⁶, Christoph Bickel³⁴⁴, Hans J. Rupprecht³⁴⁴, Claire Perret³⁴⁶, Carole Proust³⁴⁶, Thomas F. Münzel³⁴⁴, Maja Barbalic³⁴, Ida Yii-Der Chen²²⁰, Serkalem Demissie-Banjaw^{246,347}, Aaron Folsom³⁴⁸, Thomas Lumley²⁷⁵, Kristin Marcic³⁴⁹, Kent D. Taylor²²⁰, Kelly Volcik³⁵⁰, Solveig Gretarsdottir³³², Jeffrey R. Gulcher³³², Augustine Kong³³², Kari Stefansson^{332,333}, Gudmundur Thorgeirsson^{333,351}, Karl Andersen^{333,351}, Marcus Fischer³²⁸, Anika Grosshennig^{324,329}, Patrick Linsel-Nitschke³²⁴, Klaus Stark³²⁸, Stefan Schreiber³⁸, Zouhair Aherrahou^{57,324}, Petra Bruse^{57,324}, Angela Doering³⁵², Norman Klopp³⁵², Patrick Diemert³²⁴, Christina Loley^{324,329}, Anja Medack^{57,324}, Janja Nahrstedt^{324,329}, Annette Peters⁶⁸, Arnika K. Wagner³²⁴, Christina Willenborg^{57,324}, Bernhard O. Böhm³⁵³, Harald Dobnig³⁵⁴, Tanja B. Grammer³⁵⁵, Michael M. Hoffmann³⁵⁶, Andreas Meinitzer³⁵⁷, Bernhard R. Winkelmann³⁵⁸, Stefan Pilz³⁵⁴, Wilfried Renner³⁵⁷, Hubert Scharnagl³⁵⁷, Tatjana Stojakovic³⁵⁷, Andreas Tomaschitz³⁵⁴, Karl Winkler³⁵⁶, Candace Guiducci¹⁶, Noel Burt¹⁶, Stacey B. Gabriel¹⁶, Sonny Dandona³³¹, Olga Jarinova³³¹, Liming Qu³³⁸, Robert Wilensky³²³, William Matthai³²³, Hakon H. Hakonarson³⁵⁹, Joe Devaney³⁶⁰, Mary Susan Burnett³⁶⁰, Augusto D. Pichard³⁶⁰, Kenneth M. Kent³⁶⁰, Lowell Satler³⁶⁰, Joseph M. Lindsay³⁶⁰, Ron Waksman³⁶⁰, Christopher W. Knouff³⁶¹, Dawn M. Waterworth³⁶¹, Max C. Walker³⁶¹, Stephen E. Epstein³⁶⁰, Daniel J. Rader^{323,362}, Christopher P. Nelson¹⁸⁵, Benjamin J. Wright³⁶³, Anthony J. Balmforth³⁶⁴, Stephen G. Ball³⁶⁵

³²³The Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. ³²⁴Institut für integrative und experimentelle Genomik, Universität zu Lübeck, Lübeck 23562, Germany. ³²⁵Deutsches Herzzentrum München, Technische Universität München, München 80636, Germany. ³²⁶Department of Medicine, Stanford University School of Medicine, Stanford, 94305-5101 California, USA. ³²⁷Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK. ³²⁸Klinik und Poliklinik für Innere Medizin II, Universität Regensburg, 93053 Regensburg, Germany. ³²⁹Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, 23562 Lübeck, Germany. ³³⁰Science Center, Tampere University Hospital, Tampere 33521, Finland. ³³¹The John & Jennifer Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada K1Y 4W7. ³³²deCODE Genetics, Reykjavik 101, Iceland. ³³³Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland. ³³⁴Hudson Alpha Institute, Huntsville, 35806 Alabama, USA. ³³⁵Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada K1Y 4W7. ³³⁶The Blavatnik School of Computer Science, Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv 6997801, Israel. ³³⁷The International Computer Science Institute, Berkeley, 94704 California, USA. ³³⁸Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, 19104 Pennsylvania, USA.

³³⁹Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, 02114 Massachusetts, USA. ³⁴⁰Center for Human Genetic Research, Massachusetts General Hospital, Boston, 02114 Massachusetts, USA. ³⁴¹Division of Research, Kaiser Permanente, Oakland, 94611 California, USA. ³⁴²Institute for Human Genetics, University of California, San Francisco, San Francisco, 94143 California, USA. ³⁴³Department of Cardiovascular Medicine, Cleveland Clinic 7255 Old Oak Blvd, Cleveland, Ohio 44130, USA. ³⁴⁴Medizinische Klinik und Poliklinik, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, 55122 Mainz, Germany. ³⁴⁵Institut für Klinische Chemie und Laboratoriumsmedizin, Johannes-Gutenberg Universität Mainz, Universitätsmedizin, 55122 Mainz, Germany. ³⁴⁶INSERM UMRS 937, Pierre and Marie Curie University (UPMC, Paris 6) and Medical School, 75005 Paris, France. ³⁴⁷Boston University, School of Public Health, Boston, 02118 Massachusetts, USA. ³⁴⁸University of Minnesota School of Public Health, Division of Epidemiology and Community Health, School of Public Health (A.R.F.), Minneapolis, 55454 Minnesota, USA. ³⁴⁹University of Washington, Department of Internal Medicine, Seattle, 98195-6420 Washington, USA. ³⁵⁰University of Texas, School of Public Health, Houston, 77030 Texas, USA. ³⁵¹Department of Medicine, Landspítali University Hospital, Reykjavik 101, Iceland. ³⁵²Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany. ³⁵³Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes, University of Ulm, 89069 Ulm, Germany. ³⁵⁴Division of Endocrinology, Department of Medicine, Medical University of Graz, 8010 Graz, Austria. ³⁵⁵Synlab Center of Laboratory Diagnostics Heidelberg, 69037 Heidelberg, Germany. ³⁵⁶Division of Clinical Chemistry, Department of Medicine, Albert Ludwigs University, 79085 Freiburg, Germany. ³⁵⁷Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, 8010 Graz, Austria. ³⁵⁸Cardiology Group Frankfurt-Sachsenhausen, 60594 Frankfurt, Germany. ³⁵⁹The Center for Applied Genomics, Children's Hospital of Philadelphia, 19104 Philadelphia, Pennsylvania, USA. ³⁶⁰Cardiovascular Research Institute, Medstar Health Research Institute, Washington Hospital Center, Washington, DC 20010, USA. ³⁶¹Genetics Division and Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA. ³⁶²The Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, Philadelphia, 19104-5158 Pennsylvania, USA. ³⁶³Department of Cardiovascular Surgery, University of Leicester, Leicester LE1 7RH, UK. ³⁶⁴Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds LS2 9JT, UK. ³⁶⁵LIGHT Research Institute, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.

CHARGE-Heart Failure Group

Laura R. Loehr^{366,367,368}, Wayne D. Rosamond³⁶⁷, Emelia Benjamin²⁴⁷, Talin Haritunians²²⁰, David Couper³⁶⁹, Joanne Murabito²⁴⁷, Ying A. Wang¹³, Bruno H. Stricker²⁴, Patricia P. Chang³⁶⁶, James T. Willerson^{370,371}

³⁶⁶Department of Medicine, University of North Carolina at Chapel Hill, North Carolina 27516, USA. ³⁶⁷Department of Epidemiology, University of North Carolina at Chapel Hill, North Carolina 27599-7435, USA. ³⁶⁸National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA. ³⁶⁹Department of Biostatistics, University of North Carolina at Chapel Hill, North Carolina 27514, USA. ³⁷⁰University of Texas, Houston Health Science Center, Houston, Texas 77030, USA. ³⁷¹Texas Heart Institute, Houston, Texas 77225-0345, USA.

ECHOGen Consortium

Stephan B. Felix²⁰², Norbert Watzinger³⁷², Jayashri Aragam²⁴⁷, Robert Zweiker³⁷², Lars Lind³⁷³, Richard J. Rodeheffer³⁷⁴, Karin Halina Greiser³⁷⁵, Jaap W. Deckers³⁷⁶, Jan Stritzke³⁷⁷, Erik Ingelsson³⁷⁸, Iftikhar Kullo³⁷⁴, Johannes Haerting³⁷⁵, Thorsten Reffelmann²⁰², Margaret M. Redfield³⁷⁴, Karl Werdan³⁷⁹, Gary F. Mitchell²⁴⁷, Donna K. Arnett³⁸⁰, John S. Gottdiener³⁸¹, Maria Blettner³⁸², Nele Friedrich³⁸³

³⁷²Department of Internal Medicine, Division of Cardiology, Medical University Graz, Graz 8036, Austria. ³⁷³Department of Medical Sciences, Uppsala University, Uppsala 75185, Sweden. ³⁷⁴Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA. ³⁷⁵Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University of Halle-Wittenberg, Halle-Wittenberg, Halle (Saale) 06097, Germany. ³⁷⁶Department of Cardiology, Erasmus University Medical Center, Rotterdam 3000 CA, The Netherlands. ³⁷⁷Medical Clinic 2, University of Lübeck, Lübeck 23538, Germany. ³⁷⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 17177, Sweden. ³⁷⁹Martin Luther University, Halle-Wittenberg, Halle (Saale) 06097, Germany. ³⁸⁰Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0022, USA. ³⁸¹Division of Cardiology, University of Maryland Hospital, Baltimore, Maryland 21201, USA. ³⁸²Institute of Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg University, Mainz 55101, Germany. ³⁸³Institute for Community Medicine, Ernst-Moritz-Arndt-Universität, Greifswald 17475, Germany.